On this page
Quick Reference
Overview and Recommendations
Background
- •Marfan syndrome is an autosomal dominant connective tissue disorder caused by pathogenic variants in , the gene encoding fibrillin-1, leading to dysregulated signaling that drives progressive aortic root dilation and multisystem manifestations spanning skeletal, ocular, cardiovascular, and pulmonary systems.
- •With an estimated prevalence of 1 in 5,000 to 1 in 10,000, Marfan syndrome carries a high morbidity and mortality primarily from aortic root aneurysm and dissection, the annual risk of dissection rises from 0.09% at aortic diameters <40 mm to 1.33% at 50-54 mm.
- •The 2010 revised Ghent criteria establish the diagnosis using two major scenarios: aortic root dilation (z-score ≥2) or dissection plus ectopia lentis; or aortic root disease plus a pathogenic variant, with a systemic score ≥7 points providing additional diagnostic support.
- •Cardiovascular involvement is the leading cause of death and includes , with (present in ~34% of patients), and a primary cardiomyopathy independent of valvular disease.
- •Prophylactic aortic root replacement at ≥50 mm (or ≥45 mm with rapid growth >2 mm/year, family history of dissection, or severe aortic regurgitation) is the cornerstone of prevention; valve-sparing root replacement (David procedure) is the preferred elective technique.
- •Approximately 25% of cases are de novo mutations, and men carry a higher aortic risk (HR 1.4 for aortic events). Family history of dissection is the strongest risk factor (RR 6.82).
Evaluation
- •Suspect Marfan syndrome in any young patient presenting with aortic dissection, ectopia lentis, spontaneous pneumothorax, or unexplained tall stature with arachnodactyly and joint hypermobility.
- •Ask about family history of aortic dissection, sudden cardiac death, or known connective tissue disorders, first-degree relatives of an affected proband have a relative risk of 6.82 for aortic dissection.
- •Ask about ocular symptoms: blurred vision from lens subluxation (ectopia lentis, typically superotemporal), myopia, or history of retinal detachment; these are often presenting complaints.
- •Ask about skeletal symptoms: joint hypermobility, scoliosis, pectus deformity (excavatum or carinatum), flat feet, and prior spontaneous pneumothorax.
- •Examine for the wrist sign (overlap of thumb and little finger around the opposite wrist) and thumb sign (thumb protrudes beyond ulnar border when hand is clenched), both together score 3 points on the Ghent systemic score.
- •Examine for pectus carinatum (2 points), pectus excavatum (1 point), hindfoot valgus (2 points), pes planus (1 point), scoliosis ≥20° (1 point), reduced elbow extension ≤170° (1 point), and characteristic facial features: dolichocephaly, enophthalmos, downslanting palpebral fissures, malar hypoplasia, retrognathia (1 point if 3 of 5 present).
- •Auscultate for a mid-systolic click (mitral valve prolapse, 1 point) and a diastolic murmur (aortic regurgitation). Note that is present in >60% and may cause low back pain or radicular symptoms.
- •Order as first-line imaging: measure aortic root diameter at the sinuses of Valsalva in end-diastole, leading edge to leading edge, and calculate a z-score adjusted for age and body surface area (z-score ≥2 is abnormal; absolute ≥40 mm is dilated in adults).
- •Order cardiac magnetic resonance or computed tomography angiography of the entire aorta at baseline to assess beyond the root: check for (VTI ≥50 predicts earlier dissection), aortic branch aneurysms (present in 27% and independently predict need for surgery, HR 3.4), and dural ectasia.
- •Apply the revised Ghent criteria: if the patient has aortic root dilation/dissection plus ectopia lentis, the diagnosis is established regardless of genetic testing. If aortic root disease is present without ectopia lentis, a pathogenic mutation or a systemic score ≥7 is required.
- •Order genetic testing (targeted next-generation sequencing) to confirm the diagnosis and inform genotype-phenotype correlations: variants confer higher aortic risk (HR 2.5 for cardiovascular death) and a 60% incidence of pregnancy-related dissection.
- •If FBN1 testing is negative but clinical suspicion remains high, order a multigene panel for heritable thoracic aortic disease including , , , , and to rule out Loeys-Dietz syndrome and vascular Ehlers-Danlos syndrome.
- •Also consider differential diagnoses: (bifid uvula, hypertelorism, arterial tortuosity, dissection at smaller diameters), (easy bruising, thin skin, visceral rupture), familial thoracic aortic aneurysm syndrome (isolated aortic dilation, no systemic features), and MASS phenotype (myopia, MVP, borderline aortic root, no ectopia lentis, no dissection).
- •Screen all first-degree relatives with echocardiography and genetic counseling if the proband has a confirmed pathogenic FBN1 variant or meets Ghent criteria clinically.
- •In children, use aortic z-scores against published normative data; annual echo is standard, with more frequent imaging (every 6 months) if z-score >3 or rapid dilation is detected.
Management
- •For acute aortic dissection, immediately administer IV (esmolol 250-500 μg/kg loading dose then 50-200 μg/kg/min, or labetalol 10-20 mg IV every 10 minutes) to achieve heart rate <60 bpm and systolic BP 100-120 mm Hg; add IV vasodilator (nicardipine 5 mg/h or clevidipine 1-2 mg/h) only after beta-blockade is established, monotherapy with vasodilator is dangerous due to reflex tachycardia.
- •For type A aortic dissection, perform emergency complete aortic root replacement: (David reimplantation) is preferred over supracoronary ascending replacement alone, which has a 40% reintervention rate at 20 years. If valve is irreparable, use a mechanical composite graft.
- •For uncomplicated type B dissection, medical management with beta-blockade and aggressive BP control is first-line, but given the high progression rate in Marfan (68% require late surgery), immediate multidisciplinary aortic team consultation is recommended; complicated type B (malperfusion, rupture, refractory pain, rapid expansion) requires urgent TEVAR or open repair.
- •Initiate long-term therapy as first-line for all patients with aortic root dilation: start 25 mg once daily and titrate to 50-100 mg daily (target resting heart rate 60-70 bpm, blood pressure <130/80 mm Hg). In children, weight-based dosing is used.
- •Add an as adjunctive therapy: start 25-50 mg once daily, titrate to 100 mg daily (50 mg if weight <50 kg); alternatively 75 mg once daily, increase to 150-300 mg daily. ARBs reduce the annual rate of aortic root Z-score change by approximately 50% (Class IIa recommendation).
- •Monitor blood pressure, serum potassium, and renal function when initiating or titrating ARBs; avoid ARBs during pregnancy (second and third trimesters) due to fetotoxicity.
- •Perform annual transthoracic echocardiography to measure aortic root diameter; if stable for 2 years, consider extending interval to every 2 years. In children or those with rapid progression, image every 6 months.
- •Refer for prophylactic aortic root replacement when the aortic diameter reaches ≥50 mm (or ≥45 mm with rapid growth >2 mm/year, family history of dissection, or severe ). Valve-sparing root replacement (David technique) is the preferred elective procedure.
- •Avoid in Marfan patients, they are associated with an increased risk of aortic dissection and should only be used if no alternative exists.
- •Avoid strenuous isometric exercise and heavy weightlifting; encourage moderate aerobic activity (walking, swimming, cycling). A personalized home-based exercise program can improve aerobic capacity without affecting aortic diameter.
- •In pregnancy, continue beta-blocker therapy throughout gestation, the maternal survival benefit outweighs the small risk of fetal growth restriction (mean 442 g lower birth weight). Monitor aortic root with echocardiography every 4-8 weeks.
- •Consider delivery by if the aortic root diameter exceeds 4.0 cm or if rapid dilation occurs; vaginal delivery with epidural anesthesia and a shortened second stage is an option for women with root <4.0 cm and stable dimensions.
- •Postpartum surveillance is critical: 2.7% of women experience dissection during postpartum hospitalization and 2.7% are re-hospitalized for dissection within one year; continue beta-blocker and image at 3, 6, and 12 months postpartum.
- •In children, initiate beta-blocker (atenolol or nadolol) as first-line; add if aortic dilation progresses. Annual echo with z-score monitoring; restrict competitive sports with high static/isometric demands, but encourage moderate aerobic activity.
- •Screen for (MAD >10 mm) on echocardiography, these patients have higher rates of aortic events (60% vs 21%) and ventricular arrhythmias, warranting Holter monitoring and low threshold for electrophysiology consultation.
- •Redo sternotomy is common (41% of operated patients): optimize blood pressure control (hypertension OR 2.39) and plan with a multidisciplinary aortic team. After initial root replacement, lifelong surveillance of the entire aorta is required because new distal dissection occurs in 16.5% at 15 years.
- •What NOT to do: do not treat the ascending aorta using thresholds derived from bicuspid aortic valve disease (Marfan patients face higher dissection risk); do not prescribe ARBs in pregnancy; do not use vasodilators before beta-blockers in acute aortic syndrome; do not recommend heavy weightlifting or contact sports.
- •Discharge criteria after acute dissection: stable hemodynamics, controlled BP and heart rate on oral therapy, postoperative CTA documenting residual dissection, and a clear plan for follow-up imaging at 3, 6, and 12 months, then annually.
Board Review — High Yield
- •FBN1 mutation, causes Marfan syndrome via deficient fibrillin-1 and dysregulated TGF-β signaling, leading to aortic root aneurysm, ectopia lentis, and skeletal abnormalities.
- •Revised Ghent criteria, diagnosis requires aortic root dilation (z-score ≥2) or dissection plus ectopia lentis, OR aortic root disease plus FBN1 mutation or systemic score ≥7 (points from skeletal, ocular, cardiovascular, skin features).
- •Aortic dissection risk, annual risk rises from 0.09% at <40 mm to 1.33% at 50-54 mm; prophylactic root replacement at ≥50 mm (or ≥45 mm with risk factors) is the standard.
- •Beta-blocker first-line, atenolol or propranolol targeting HR 60-70 bpm to reduce aortic wall stress and slow root dilation.
- •ARB therapy, losartan or irbesartan reduces aortic root dilation rate by ~50% via TGF-β antagonism; can be added to beta-blocker or used as alternative.
- •Valve-sparing root replacement (David procedure), preferred elective surgery for aortic root aneurysm, offering superior survival and lower reintervention rates compared to composite graft or supracoronary replacement.
- •Ectopia lentis, lens subluxation (typically superotemporal) is a cardinal ocular feature present in ~60% of patients; highly specific for Marfan syndrome when combined with aortic dilation.
- •Pregnancy risks, 5-fold increased dissection risk; continue beta-blocker; monitor aortic root every 4-8 weeks; consider C-section if root >4.0 cm; avoid ARBs in second/third trimester.
- •Mitral annular disjunction >10 mm, present in 34% of patients and associated with higher aortic event rates (60% vs 21%) and ventricular arrhythmias; warrants intensified surveillance and Holter monitoring.
- •Family screening, all first-degree relatives need echocardiography and genetic counseling; family history of dissection is the strongest risk factor (RR 6.82).
Deep Dive — Evidence Details
Definition, Classification and Nomenclature
- ▸Marfan syndrome is defined by pathogenic FBN1 variants causing increased TGF-β signaling and multisystem connective tissue fragility, with aortic root dilatation as the cardinal life-threatening manifestation.
- ▸Classification is based on genetic (FBN1 vs. TGFBR/TGFB phenocopies), clinical severity (systemic score per Ghent criteria), and anatomic involvement, each axis alters surveillance and treatment thresholds.
- ▸Prevalence is 1:5000-1:10,000; the syndrome accounts for 5% of all aortic dissections and 65% of pregnancy-related dissections, underscoring the need for early diagnosis.
Marfan syndrome (MFS) is an autosomal dominant, multisystem connective tissue disorder caused by pathogenic variants in the FBN1 gene, which encodes fibrillin-1, a critical extracellular matrix protein that regulates transforming growth factor-beta (TGF-β) bioavailability [8]D5[9]D5[27]D5. The condition affects the skeletal, ocular, cardiovascular, and pulmonary systems, with life-threatening aortic root dilatation and dissection being the predominant cause of reduced life expectancy [8]D5[18]B2b.
Synonyms and Historical Terms
- Marfan syndrome (MFS)
- FBN1-related Marfan syndrome
- Marfan's syndrome (older nomenclature)
- Acromegalic arachnodactyly (historical)
Classification Axes
MFS is classified along three axes that guide clinical :
1. Genetic/molecular: Nearly all cases result from heterozygous FBN1 loss-of-function or dominant-negative mutations [22]C4. Rarely, phenocopies arise from TGFBR1, TGFBR2, SMAD3, or TGFB2 variants (classified as , which shares aortic risk but has distinct surveillance protocols) [11]B2b[14]B2b.
2. Clinical severity: Expressivity ranges from isolated ectopia lentis to severe neonatal MFS with early-onset, rapidly progressive aortic disease. The revised Ghent criteria (2010) assign systemic, ocular, and cardiovascular domain scores to establish the diagnosis [1]A1c[8]D5.
3. Anatomic involvement: The cardiovascular phenotype includes aortic root aneurysm, mitral valve prolapse with mitral annular disjunction (present in up to 34% of patients), and a primary cardiomyopathy [20]C4[24]B2b. Extracardiac features include lens dislocation (ectopia lentis), skeletal abnormalities (scoliosis, pectus deformity, arachnodactyly), and spontaneous pneumothorax [26]D5[31]D5.
Clinical Significance
MFS has an estimated prevalence of 1:5000 to 1:10,000 individuals [8]D5. Aortic dissection is the most devastating complication; recurrent aortic dissection is strongly associated with MFS (hazard ratio 8.6 compared with non-Marfan patients) [10]C4. The 2022 ACC/AHA guideline emphasizes prophylactic aortic root replacement at aortic diameters ≥50 mm (or ≥45 mm with rapid growth or family history of dissection) to prevent catastrophic events [1]A1c[2]A1c.
Pearl: MFS should be suspected in any young patient (particularly male) presenting with aortic dissection, spontaneous pneumothorax, or ectopia lentis, one-quarter of pregnancy-related aortic dissections occur in unrecognized MFS [23]B2b[26]D5.
| Condition | Gene | Key Distinguishing Feature | Aortic Event Risk |
|---|---|---|---|
| Marfan syndrome (MFS) | FBN1 | Ectopia lentis, systemic score ≥7, aortic root dilation | High (aortic dissection, need for surgery) |
| Loeys-Dietz syndrome (LDS) | TGFBR1, TGFBR2, SMAD3, TGFB2 | Arterial tortuosity, bifid uvula, wide scarring | Very high, with earlier and more frequent peripheral arterial events [14]B2b |
| Vascular Ehlers-Danlos syndrome (vEDS) | COL3A1 | Thin translucent skin, easy bruising, visceral rupture | Highest, with early arterial events including non-aortic vessels [14]B2b |
Epidemiology and Risk Factors
- ▸Marfan syndrome prevalence is 1:5000-1:10000, with autosomal dominant inheritance and ~25% de novo mutations.
- ▸Family history of aortic dissection is the strongest risk factor (RR 6.82), and aortic diameter ≥50 mm carries a 1.33% annual dissection risk.
- ▸Pregnancy increases dissection risk 5-fold, and type B dissections now outnumber type A in contemporary cohorts.
The classification above delineates the clinical spectrum; understanding who develops Marfan syndrome and why requires examination of its population burden and the drivers of its most feared complication, .
Prevalence is 1 in 5,000 to 1 in 10,000, with no known ethnic or geographic predilection [8]D5. Approximately 25% of cases arise from de novo mutations [25]C4. Men carry higher aortic risk: by age 30, 57% of men versus 50% of women have ascending aortic dilatation, and the adjusted hazard for aortic events is HR 1.4 (95% CI 1.1-1.8) [42]B2b. Aortic involvement reaches 96% by age 60 [42]B2b. Over two decades, dissection rates have declined while dilatation prevalence has remained stable [42]B2b.
The strongest risk factor for dissection is family history: first-degree relatives have an RR of 6.82 (95% CI 5.12-9.07) [41]B2b. Heritability is 57% [41]B2b. Among Marfan patients, recurrent dissection risk is HR 8.6 (95% CI 5.8-12.8) [10]C4. Aortic diameter is critical: annual dissection risk rises from 0.09% at <40 mm to 1.33% at 50-54 mm [33]B2b. (OR 2.39 for redo sternotomy [21]B2b), male sex, and (5-fold increase [16]C4) compound risk.
| Factor | Measure of Association | 95% CI | Evidence Level |
|---|---|---|---|
| Family history of aortic dissection | RR 6.82 | 5.12-9.07 | 2b [41]B2b |
| Marfan syndrome (for recurrent AD) | HR 8.6 | 5.8-12.8 | 4 [10]C4 |
| Male sex (for aortic events) | HR 1.4 | 1.1-1.8 | 2b [42]B2b |
| Hypertension (for redo sternotomy) | OR 2.39 | 1.54-3.72 | 2b [21]B2b |
| Aortic diameter ≥50 mm (vs <40 mm) | Annual event rate 1.33% vs 0.09% | - | 2b [33]B2b |
| Pregnancy (vs non-pregnancy period) | 5-fold increase | - | 4 [16]C4 |
Pregnancy increases dissection risk 5-fold; type A dissections occur mainly in undiagnosed women [16]C4[23]B2b. Type B dissections now outnumber type A, often at descending aortic diameters <4.0 cm [38]B3b. These patterns highlight the primacy of aortic wall integrity, detailed in the next section.
Pearl: The annual risk of aortic dissection in Marfan syndrome rises from 0.09% at aortic diameters <40 mm to 1.33% at 50-54 mm, underscoring the importance of prophylactic surgery at 50 mm [33]B2b.
Pathophysiology and Mechanism
- ▸FBN1 mutation causes defective fibrillin‑1, leading to excessive TGF‑β signaling, extracellular matrix degradation, and aortic wall weakness.
- ▸Vascular smooth muscle cell metabolic dysfunction (mitochondrial failure, HBP‑ISR activation) and sterile inflammation (monocyte/macrophage infiltration) are downstream effectors that amplify aneurysm progression.
- ▸Two broad genetic categories, TGF‑β vasculopathies and smooth muscle contraction vasculopathies, converge on the final common pathway of medial degeneration and reduced aortic tensile strength.
The causal FBN1 mutation disrupts the extracellular matrix at the molecular level, setting in motion a cascade that weakens the aortic wall long before dilation becomes detectable. Mutations in FBN1, the gene encoding fibrillin-1, produce defective fibrillin-1 microfibrils that serve both a structural role in elastic fibers and a regulatory role by sequestering latent transforming growth factor‑β (TGF‑β) complexes [27]D5[34]D5[70]D5. Loss of functional fibrillin-1 liberates active TGF‑β from the extracellular matrix, leading to excessive TGF‑β signaling through its canonical (SMAD2/3) and non‑canonical (p38, ERK) pathways [34]D5[56]B3b[59]B3b. This dysregulation is the central mechanistic driver in Marfan syndrome aortopathy [5]D5[52]D5.
Core Pathogenic Cascade: From FBN1 Mutation to TGF‑β Dysregulation
- Fibrillin-1 deficiency reduces the integrity of microfibrils in the aortic media, impairing elastic fiber assembly and mechanical support [5]D5.
- Latent TGF‑β complex (LAP‑TGF‑β) is normally bound to fibrillin‑1; without it, TGF‑β is released in its active form [27]D5.
- Excess TGF‑β binds to TGF‑β receptors (TGFBR1, TGFBR2) on (VSMCs) and valvular interstitial cells, activating SMAD2/3 phosphorylation and downstream profibrotic and matrix‑remodeling gene programs [34]D5[56]B3b[59]B3b.
- Increased TGF‑β signaling upregulates matrix metalloproteinases (MMP‑12, MT1‑MMP) and downregulates tissue inhibitors (TIMP‑3), shifting the balance toward extracellular matrix degradation [56]B3b.
- Fragmented elastin and degraded fibrillin fragments themselves become chemotactic for macrophages via the elastin-binding protein (EBP), establishing a self‑perpetuating cycle of inflammation and matrix destruction [58]D5.
Aortic Wall Vulnerability: Extracellular Matrix and Smooth Muscle Cell Dysfunction
Aortic specimens from Marfan patients show a unique MMP/TIMP portfolio: decreased MMP‑2 (76±7% of control), increased MMP‑12 (161±27%) and MT1‑MMP (248±64%), reduced TIMP‑3 (74±23%), and elevated TGFBR2 (193±32%) [56]B3b. These changes promote medial degeneration characterized by elastic fiber fragmentation, proteoglycan accumulation, and collagen disarray [34]D5[56]B3b.
Beyond matrix remodeling, the structural integrity of the aortic wall depends on the VSMC contractile apparatus. Genes encoding components of smooth muscle contraction, ACTA2, MYH11, MYLK, PRKG1, constitute a second major category of inherited aortopathy mutations [34]D5. In Marfan syndrome, defective extracellular matrix impairs VSMC contractility and triggers phenotypic switching from a contractile to a synthetic, pro‑inflammatory state [5]D5[70]D5.
Mitochondrial dysfunction has emerged as a key downstream consequence. Aortas from Fbn1C1039G/+ mice and Marfan patients exhibit reduced mitochondrial complex activity, mtDNA depletion, and increased lactate production consistent with a shift to glycolytic metabolism [53]D5. VSMCs seeded on fibrillin‑1‑deficient matrices develop this mitochondrial defect, demonstrating that the extracellular environment directly controls VSMC metabolism [53]D5. Conditional deletion of Tfam (mitochondrial transcription factor A) in VSMCs causes aortic aneurysm and premature death, confirming that mitochondrial failure is sufficient to drive aortopathy [53]D5. Restoring mitochondrial respiration with the NAD precursor nicotinamide riboside reverses aneurysm progression in mice [53]D5.
| Genetic Pathway | Key Genes | Mechanistic Consequence |
|---|---|---|
| TGF‑β vasculopathies | FBN1, TGFBR1, TGFBR2, TGFB2, TGFB3, SMAD2, SMAD3, SKI | Excessive TGF‑β signaling → matrix degradation, VSMC dysfunction |
| Smooth muscle contraction vasculopathies | ACTA2, MYH11, MYLK, PRKG1 | Impaired VSMC contraction → aortic wall weakness |
| Extracellular matrix | FBN1, biglycan, decorin, fibulin‑1 | Microfibril disruption, collagen fragility, reduced tensile strength |
Adapted from [34]D5[55]D5[56]B3b[70]D5.
Inflammation and Metabolic Reprogramming
Macrophage infiltration is an early and sustained feature of Marfan aortopathy. Monocyte‑derived (CCR2+, MHCII+) and resident (CD206+) macrophages accumulate in the aortic media and in myxomatous mitral valves, contributing to medial degeneration and valve thickening [54]D5[58]D5. In Fbn1C1039G/+ mice, deficiency of circulating monocytes (by CCR2 knockout) protects against myxomatous valve degeneration, reducing leaflet thickening and preserving valve integrity [54]D5. These findings identify sterile inflammation as a therapeutic target [54]D5.
More recently, the hexosamine biosynthetic pathway (HBP) and integrated stress response (ISR) have been implicated. HBP is upregulated in Marfan mouse aortas and in human tissue specimens, leading to excessive protein glycosylation that drives VSMC dysfunction and medial degeneration via ISR activation [63]D5. Pharmacological inhibition of HBP or ISR reverses aortic dilation in the Marfan mouse model [63]D5.
Pearl: The mechanistic link between fibrillin‑1 deficiency and TGF‑β hyperactivity explains why and β‑blockers both show benefit, but neither halts disease, targeting distal nodes (mitochondrial metabolism, HBP‑ISR, or monocyte recruitment) may be required for additive or superior effect [52]D5[53]D5[54]D5[63]D5.
Clinical Presentation
- ▸Marfan syndrome presents with a characteristic tall, thin habitus, arachnodactyly, pectus deformity, ectopia lentis, and aortic root dilation; many patients are asymptomatic until a catastrophic aortic dissection or pneumothorax.
- ▸Bedside maneuvers (wrist sign, thumb sign) and auscultatory findings (mid-systolic click, diastolic murmur) aid in clinical recognition.
- ▸Phenotypic variants exist: FBN1 haploinsufficiency confers higher aortic risk, while TGFBR2 mutations may present without classic skeletal features.
From the defective fibrillin-1 and excessive TGF-β signaling emerges a recognizable clinical phenotype that spans multiple organ systems, though the initial presentation may be subtle or catastrophic.
Presenting Symptoms
Patients may come to attention through incidental findings of tall stature and arachnodactyly during routine examination, family screening after a proband is diagnosed, or acute events such as aortic dissection (tearing chest/back pain), ectopia lentis (blurred vision), or spontaneous pneumothorax (sudden dyspnea) [26]D5. Many remain asymptomatic until a life-threatening complication occurs.
Cardiovascular Examination
Aortic root dilation is the hallmark; it is often silent until dissection. On auscultation, a mid-systolic click suggests mitral valve prolapse (present in ~40% of patients [12]C4), and a diastolic murmur indicates . The wrist sign (overlap of thumb and little finger around the opposite wrist) and thumb sign (thumb protrudes beyond ulnar border when hand is clenched) are simple bedside tests for arachnodactyly.
Skeletal Examination
Tall stature with arm span-to-height ratio >1.05, pectus deformity (excavatum or carinatum), scoliosis, joint hypermobility, and pes planus are common. These features contribute to the Ghent criteria.
Ocular Findings
Ectopia lentis (lens subluxation) is a cardinal feature, typically superotemporal, and is present in ~60% of patients [22]C4. It may cause myopia or astigmatism. is a less common but vision-threatening complication.
Neurological and Dural Findings
Dural ectasia, present in >60% of patients, may cause low back pain, radicular symptoms, or . Examination may reveal lower extremity weakness, sensory loss, or sphincter dysfunction.
Red Flags
Acute onset of severe chest or back pain should prompt immediate imaging for aortic dissection. Sudden dyspnea with pleuritic pain suggests pneumothorax. Acute vision loss requires urgent ophthalmologic evaluation.
Atypical Presentations
Some patients, particularly those with TGFBR2 mutations, may present with aortic dissection without classic skeletal features [11]B2b. Isolated mitral valve prolapse or aortic root dilation in a young individual should raise suspicion.
Phenotypic Variants
| Variant Class | Key Features | Frequency |
|---|---|---|
| FBN1 haploinsufficiency | Higher risk of aortic events (RR 2.62 vs DN), larger baseline aortic root diameter [74]A1a | ~30% of FBN1 |
| FBN1 dominant negative (missense, cysteine) | Moderate risk; cysteine substitutions increase aortic event risk (RR 2.21) [74]A1a | ~60% of FBN1 |
| TGFBR2 mutation | Similar aortic outcomes to FBN1 but less mitral valve involvement; may present without classic skeletal features [11]B2b | Rare |
Pearl: The combination of tall stature, arachnodactyly, ectopia lentis, and aortic root dilation is virtually diagnostic; however, the absence of skeletal features does not exclude Marfan syndrome, especially in patients with TGFBR2 mutations [11]B2b.
Diagnosis and Workup
- ▸Diagnosis is established using the 2010 revised Ghent criteria, which integrate aortic root measurement (z-score ≥2), ectopia lentis, and a systemic point score (≥7) with or without an FBN1 mutation.
- ▸Genetic testing for FBN1 identifies >90% of clinically defined cases; haploinsufficient variants convey higher risk for early dissection and pregnancy complications.
- ▸Baseline whole-aorta imaging (CTA or CMR) is mandatory to detect branch aneurysms, vertebral tortuosity, and dural ectasia, all of which refine risk stratification.
From the clinical features described, the formal diagnosis of Marfan syndrome rests on the integrated application of the 2010 revised Ghent criteria, which weigh skeletal, ocular, cardiovascular, and genetic manifestations to provide a standardized framework [2]A1c[6]D5. The diagnosis is established when a patient meets one of two scenarios: (1) aortic root dilation (z-score ≥2) or aortic dissection plus ectopia lentis, with or without a systemic score; or (2) aortic root disease plus a pathogenic FBN1 mutation, regardless of other features [2]A1c.
Revised Ghent Criteria
The criteria classify involvement across seven domains. A systemic score ≥7 (of 20 possible points) supports the diagnosis when combined with aortic root disease or a FBN1 mutation [6]D5.
| Domain | Feature | Points |
|---|---|---|
| Skeletal (wrist and thumb sign) | Wrist AND thumb sign | 3 |
| Skeletal (wrist OR thumb sign) | One sign only | 1 |
| Skeletal (pectus deformity) | 2 | |
| Skeletal ( or chest asymmetry) | Pectus excavatum or asymmetry | 1 |
| Skeletal (hindfoot deformity) | Hindfoot valgus | 2 |
| Skeletal (pes planus) | Flat feet | 1 |
| Skeletal (pneumothorax) | Spontaneous pneumothorax | 2 |
| Skeletal (dural ectasia) | Dural ectasia by imaging | 2 |
| Skeletal (protrusio acetabuli) | Protrusio acetabuli (radiographically) | 2 |
| Skeletal (reduced upper segment/lower segment ratio AND increased arm span/height ratio) | Both | 1 |
| Skeletal (scoliosis or thoracolumbar kyphosis) | Scoliosis ≥20° or kyphosis | 1 |
| Skeletal (reduced elbow extension) | ≤170° | 1 |
| Skeletal (facial features) | 3 of 5: dolichocephaly, enophthalmos, downslanting palpebral fissures, malar hypoplasia, retrognathia | 1 |
| Skin (striae) | Striae atrophicae not related to weight changes | 1 |
| Skin (myopia) | Myopia >3 diopters | 1 |
| Skin (mitral valve prolapse) | MVP (any grade) | 1 |
Cardiovascular major criterion: Aortic root dilation (z-score ≥2 in adults or ≥2 in children adjusted for age and body surface area) or aortic dissection [1]A1c[2]A1c. Ocular major criterion: Ectopia lentis (lens dislocation) - the most specific ocular sign [22]C4.
Genetic Testing
A pathogenic or likely pathogenic variant in FBN1 is identified in >90% of patients who meet clinical criteria [25]C4. Targeted next-generation sequencing of FBN1 is the preferred first-line molecular test [88]D5. Whole-exome or whole-genome sequencing may be useful when the phenotype is atypical or when other heritable thoracic aortic disease genes (TGFBR1, TGFBR2, SMAD3, TGFB2, COL3A1, etc.) are considered [14]B2b[11]B2b. Genotype-phenotype correlations are emerging: haploinsufficient (HI) variants (those that lead to reduced fibrillin-1 protein) are associated with more severe aortic disease, earlier aortic surgery, and a 60% incidence of pregnancy-related aortic dissection compared with 10% for non-HI mutations [79]B2b. The presence of a FBN1 mutation alone - without aortic dilation or ectopia lentis - does not satisfy Ghent criteria; clinical expression is required [2]A1c.
Imaging Assessment
Transthoracic echocardiography is the first-line imaging modality. Aortic root diameter is measured at the sinuses of Valsalva (end-diastole, leading edge to leading edge) and indexed to age and body surface area to derive a z-score. An aortic root z-score ≥2 or an absolute diameter ≥40 mm in adults is considered dilated [2]A1c[8]D5. In children, z-scores must be interpreted against published normative pediatric data [4]A1c.
Cardiovascular magnetic resonance (CMR) or computed tomography angiography (CTA) of the entire aorta is recommended at baseline and periodically during follow-up to assess beyond the aortic root [1]A1c[2]A1c. These modalities detect:
- Vertebral artery tortuosity: A vertebral tortuosity index (VTI) ≥50 is associated with earlier onset of dissection and death [76]B2b.
- Aortic branch aneurysms: Present in 26.7% of patients, most commonly in the iliac arteries; their presence independently predicts need for aortic surgery (HR 3.4, 95% CI 1.1-10.3) [15]B2b.
- Aberrant subclavian artery: Found in 2.4% of patients with heritable arteriopathies, with dissection risk ≈24% when associated with Kommerell diverticulum [17]C4.
Additional imaging findings include dural ectasia (widening of the spinal canal on MRI), protrusio acetabuli (on hip radiographs), and mitral annular disjunction (MAD; associated with arrhythmic events) [24]B2b[2]A1c.
Differential Diagnosis
| Condition | Key Differentiating Features | Genetic Test |
|---|---|---|
| Loeys-Dietz syndrome | Bifid uvula, hypertelorism, arterial tortuosity; aortic dissection at smaller diameters | TGFBR1, TGFBR2, SMAD3, TGFB2 |
| Vascular Ehlers-Danlos syndrome | Easy bruising, thin translucent skin, visceral rupture; peripheral arterial events more than aortic | COL3A1 |
| Familial syndrome | No syndromic features except aortic root dilation | ACTA2, MYH11, MYLK, others |
| MASS phenotype | Myopia, MVP, aortic root dilation at upper normal limit, striae, skeletal features - but no ectopia lentis, no aortic dissection | None specific; FBN1 negative |
| Congenital contractural arachnodactyly | Crumpled ears, contractures, no ectopia lentis, no aortic involvement | FBN2 |
Diagnostic Algorithm
The following stepwise approach is recommended [2]A1c[88]D5:
- Clinical suspicion - elicited from family history, aortic root dilation on incidental imaging, or physical findings (wrist and thumb signs, pectus deformity, ectopia lentis).
- Transthoracic echocardiography - measure aortic root diameter and calculate z-score. If aortic root z-score ≥2 or absolute diameter ≥40 mm, proceed to Step 3.
- Calculate the systemic score (≥7 points supports the diagnosis).
- Perform FBN1 genetic testing - confirmatory if clinical criteria are met; also recommended for patients who partially meet criteria but in whom the diagnosis is uncertain.
- If FBN1 negative but strong clinical suspicion remains, order a multigene panel for heritable thoracic aortic disease (including TGF-β pathway genes, COL3A1, ACTA2, etc.) [14]B2b[25]C4.
- First-degree family screening - if a proband has a confirmed pathogenic FBN1 variant or satisfies Ghent criteria clinically, offer echocardiography and genetic counseling to all first-degree relatives [2]A1c[41]B2b.
Pearl: The diagnosis of Marfan syndrome can be established in a patient with aortic root dilation and ectopia lentis even without genetic testing; however, when the phenotype is incomplete or when aortic dissection occurs at a diameter <50 mm, molecular testing is mandatory to distinguish Marfan from Loeys-Dietz syndrome, which demands a lower surgical threshold and more aggressive surveillance [1]A1c[2]A1c[11]B2b.
| Feature | Points |
|---|---|
| Wrist AND thumb sign | 3 |
| Wrist OR thumb sign | 1 |
| Pectus carinatum | 2 |
| Pectus excavatum or chest asymmetry | 1 |
| Hindfoot valgus | 2 |
| Pes planus | 1 |
| Spontaneous pneumothorax | 2 |
| Dural ectasia | 2 |
| Protrusio acetabuli | 2 |
| Reduced upper segment/lower segment ratio AND increased arm span/height ratio | 1 |
| Scoliosis ≥20° or thoracolumbar kyphosis | 1 |
| Reduced elbow extension (≤170°) | 1 |
| Facial features (3 of 5: dolichocephaly, enophthalmos, downslanting palpebral fissures, malar hypoplasia, retrognathia) | 1 |
| Striae atrophicae | 1 |
| Myopia >3 diopters | 1 |
| Mitral valve prolapse (any grade) | 1 |
| Condition | Key Differentiating Features | Genetic Test |
|---|---|---|
| Loeys-Dietz syndrome | Bifid uvula, hypertelorism, arterial tortuosity; aortic dissection at smaller diameters | TGFBR1, TGFBR2, SMAD3, TGFB2 |
| Vascular Ehlers-Danlos syndrome | Easy bruising, thin translucent skin, visceral rupture; peripheral arterial events > aortic | COL3A1 |
| Familial thoracic aortic aneurysm | No syndromic features except aortic root dilation | ACTA2, MYH11, MYLK, others |
| MASS phenotype | Myopia, MVP, borderline aortic root, striae, skeletal features; no ectopia lentis, no dissection | None specific; FBN1 negative |
| Congenital contractural arachnodactyly | Crumpled ears, contractures, no ectopia lentis, no aortic involvement | FBN2 |
Severity Staging and Risk Stratification
- ▸Aortic diameter <50 mm in treated patients carries low risk (0.4 events/1,000 patient-years for type A dissection) [39].
- ▸Vertebral Tortuosity Index ≥50 and proximal aorta longitudinal strain independently predict adverse outcomes beyond diameter [76][19].
- ▸Genotype-guided risk: IFVs in the DNCD region confer the highest risk for mitral valve surgery (HR 7.83 for age ≤30) [90].
Once the diagnosis of Marfan syndrome is established, the central task becomes stratifying the patient's risk for aortic dissection and other cardiovascular events to guide the timing of prophylactic intervention. Aortic diameter alone is a poor predictor of risk, with many patients dissecting below current intervention thresholds [5]D5. In treated patients with FBN1 pathogenic variants who receive beta-blocker therapy and limit strenuous exercise, the risk for type A dissection remains low when maximal aortic diameter is <50 mm (0.4 events/1,000 patient-years) [39]B2b. However, additional markers refine this assessment.
Imaging-Based Risk Markers
Vertebral Tortuosity Index (VTI) ≥50, measured by magnetic resonance angiography, is a reproducible marker of adverse outcomes. Patients with VTI ≥50 experience earlier age at dissection and death compared with those with VTI <50 (P=0.001 and P<0.001, respectively) [76]B2b. Proximal aorta longitudinal strain assessed by cardiac magnetic resonance independently predicts aortic root dilation rate (P=0.001) and aortic events (P=0.023) after adjustment for aortic root diameter and clinical risk factors [19]B2b. Aortic branch aneurysms are present in 26.7% of patients and independently predict the need for aortic surgery (HR 3.4; 95% CI 1.1-10.3; P=0.028) [15]B2b.
Genotype-Guided Risk Stratification
FBN1 mutation type and location stratify risk beyond aortic diameter. In-frame variants (IFVs) within the DNCD region (exons 26-37 and 44-50) confer the highest risk for mitral valve surgery, with a 30-year cumulative incidence of 23.8% (95% CI 11.7%-35.9%) and an HR of 7.83 (95%; P<0.001) for patients aged ≤30 years compared with premature termination codon variants [90]B2b. Neonatal Marfan syndrome, caused by mutations in a specific FBN1 region, carries a severe phenotype with rapidly progressive cardiovascular disease and poor prognosis [94]C4.
Clinical Risk Scores and Models
A risk model for type B aortic dissection identifies prior prophylactic aortic surgery (HR 2.1; 95% CI 1.2-3.8; P=0.010) and proximal descending aorta diameter ≥27 mm (HR 2.2; 95% CI 1.1-4.3; P=0.020) as independent predictors. The 10-year occurrence of type B dissection in low-, moderate-, and high-risk patients is 6%, 19%, and 34%, respectively [89]B2b. Angiotensin II receptor blocker therapy is associated with fewer type B dissections (HR 0.3; 95% CI 0.1-0.9; P=0.030) [89]B2b. Family history of aortic dissection is a strong risk factor (RR 6.82; 95% CI 5.12-9.07), with heritability estimated at 57% [41]B2b. The Aortic and Arterial Vulnerability Spectrum (AAVS) framework proposes integrating substrate vulnerability (assessed via skin biopsy), clinical fragility, and mechanisms of failure into a composite risk score, though validation is ongoing [68]D5.
Special Populations
Pregnancy increases dissection risk 5-fold compared with the non-pregnancy period. Type A dissection occurs only in women unaware of their diagnosis; those with prepartum aortic diameters between 4.0 and 4.5 cm demonstrate stable dimensions throughout pregnancy [16]C4. Ocular phenotype clustering identifies four subgroups with distinct genetic and prognostic characteristics, with Cluster D (extremely long axial length) showing a greater proportion of haploinsufficiency variants and worse visual prognosis [48]B2b.
Pearl: Aortic diameter alone underestimates risk; integrate vertebral tortuosity index, proximal aorta longitudinal strain, and genotype to refine surgical timing, especially in patients with prior aortic surgery or descending aorta diameter ≥27 mm.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Pregnancy threshold for prophylactic root replacement | AHA/ACC: consider surgery at 4.0 cm if planning pregnancy | ESC: recommend surgery at 4.5 cm | Moderate | U.S. guidelines may be overly restrictive; recent data support stable diameters at 4.0-4.5 cm [16]C4 |
| Role of beta-blockers in risk reduction | AHA/ACC: first-line therapy | Recent meta-analysis: no evidence of benefit for aortic events (RR 0.74; 95% CI 0.20-2.71) [46]A1a | Low | Guideline recommendations may need revision pending larger RCTs |
| Tool | Threshold / Finding | Risk Implication | Reference |
|---|---|---|---|
| Aortic root diameter | <50 mm (treated) | Low risk for type A dissection (0.4 events/1,000 pt-yrs) | [39]B2b |
| Vertebral Tortuosity Index (VTI) | ≥50 | Earlier dissection and death | [76]B2b |
| Proximal aorta longitudinal strain (CMR) | Lower strain | Independent predictor of dilation rate and aortic events | [19]B2b |
| Aortic branch aneurysms | Any | HR 3.4 for need for aortic surgery | [15]B2b |
| FBN1 genotype (DNCD region IFVs) | Exons 26-37, 44-50 | HR 7.83 for mitral valve surgery (age ≤30) | [90]B2b |
| Family history of aortic dissection | First-degree relative | RR 6.82 for aortic dissection | [41]B2b |
| Type B dissection risk model | Prior aortic surgery + descending aorta ≥27 mm | 10-year risk: 6% (low), 19% (moderate), 34% (high) | [89]B2b |
Acute and Initial Management
- ▸Acute management of Marfan-related aortic dissection requires immediate intravenous beta-blockade (target HR <60, SBP 100-120) followed by contrast CTA; emergency root replacement (VSRR preferred over supracoronary) is mandatory for type A.
- ▸Type B dissection in Marfan is often aggressive - up to 68% require eventual surgery; early consultation with a multidisciplinary aortic team is essential even for uncomplicated cases.
- ▸Post-dissection surveillance with serial CTA and lifelong combination beta-blocker + ARB therapy are critical to reduce the risk of reintervention and distal aortic complications.
Once risk stratification identifies an aortic diameter at or above the surgical threshold or a patient presents with acute chest/back pain, the time-sensitive protocol for acute aortic syndrome (AAS) begins. In Marfan syndrome, the trigger is often a sudden tear from a dilated aortic root or a type B dissection from a mildly enlarged descending aorta [39]B2b[89]B2b. The pathway divides into medical stabilization, immediate imaging, and surgical decision-making.
Step 1: Initial Assessment and Diagnosis
Any Marfan patient with severe chest or back pain, hypotension, syncope, or pulse deficit requires immediate whole-body CTA (Class I, ACC/AHA 2022) [1]A1c. Transesophageal echocardiography can be used if CTA is unavailable but is operator-dependent. The diagnosis of AAS is confirmed by the presence of an intimal flap and false lumen.
Step 2: Medical Stabilization
Simultaneously, reduce aortic wall stress. Administer an intravenous (e.g., esmolol 250-500 μg/kg loading dose then 50-200 μg/kg/min, or labetalol 10-20 mg IV over 2 minutes repeated every 10 minutes) to achieve a heart rate <60 bpm and systolic BP 100-120 mm Hg (Class I) [1]A1c. After heart rate is controlled, add an intravenous vasodilator (nicardipine 5 mg/h titrated to effect or clevidipine 1-2 mg/h) if SBP remains >120 mm Hg. Monotherapy with vasodilator before β-blocker is dangerous because reflex tachycardia worsens aortic wall stress. Pain control with intravenous further reduces sympathetic surge.
Step 3: Surgical Decision
For type A dissection (involving ascending aorta), emergency surgery is mandatory (Class I) [1]A1c. Operative mortality increases 1-2% per hour without repair. For type B dissection (descending aorta only), decide based on whether it is complicated: malperfusion, rupture, refractory pain, rapid expansion, or periaortic hematoma. Uncomplicated type B dissection can be managed medically with continued β-blockade and aggressive BP control. Complicated type B requires urgent TEVAR or open repair. In Marfan syndrome, however, the natural history of type B dissection is aggressive, up to 68% require surgical intervention during follow-up [82]B2b, and the 10-year risk of type B dissection in a moderate-risk profile is 19% [89]B2b. Thus, any type B dissection in a Marfan patient warrants immediate consultation with a multidisciplinary aortic team.
Step 4: Surgical Principles
In Marfan syndrome with type A dissection, the ACC/AHA guideline recommends complete aortic root replacement (valve-sparing root replacement [VSRR] or composite graft) rather than supracoronary ascending replacement alone (Class I) [1]A1c[36]B2b. Supracoronary repair carries a reintervention rate of 40% at 20 years [36]B2b. Meta-analysis shows VSRR is associated with better long-term survival than conservative root approach (HR 0.74, p=0.004) [45]B2a. Concomitant hemiarch or total arch replacement should be performed if the primary intimal tear is in the arch or the arch is aneurysmal.
Step 5: Post-Operative Monitoring and Transition
Before discharge, obtain a CTA of the entire aorta to document residual dissection and distal aortic diameter. Repeat imaging at 3, 6, and 12 months, then annually. The patient should be transitioned to long-term guideline-directed medical therapy (beta-blocker plus angiotensin receptor blocker) [97]A1b[99]A1a.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Role of early TEVAR for uncomplicated type B dissection in Marfan | ACC/AHA 2022: medical management alone is first-line for uncomplicated type B [1]A1c | Clinical data: high progression and need for late surgery in Marfan (68% in Cornell registry) suggests earlier intervention may reduce risk [82]B2b | Moderate | Individualized decision; close surveillance essential if medical management chosen |
Pearl: For acute type A dissection in Marfan syndrome, immediate β-blocker to achieve HR <60, emergent complete root replacement with VSRR (not supracoronary alone) and postoperative continuation of β-blocker plus ARB reduces reintervention and mortality [1]A1c[36]B2b[45]B2a.
| Drug | Starting Dose | Target | Key Monitoring |
|---|---|---|---|
| Esmolol | 250-500 μg/kg IV bolus, then 50-200 μg/kg/min infusion | HR <60 bpm, SBP 100-120 mm Hg | Heart rate, BP, bronchospasm |
| Labetalol | 10-20 mg IV over 2 min, repeat q10min up to 300 mg total | Same | Same + avoid in heart block |
| Nicardipine | 5 mg/h IV infusion, titrate by 2.5 mg/h q15min | SBP 100-120 mm Hg after HR control | Hypotension, reflex tachycardia (use after β-blocker) |
| Clevidipine | 1-2 mg/h IV, double q90s to target | SBP 100-120 mm Hg | Same |
| Morphine | 2-4 mg IV q5-15min PRN | Pain reduction, sympathetic dampening | Respiratory depression, sedation |
Long-term Guideline-Directed Therapy
- ▸Beta-blockers are first-line therapy (ACC/AHA Class I) to reduce aortic wall stress and slow aortic root dilation.
- ▸Angiotensin receptor blockers (losartan, irbesartan) reduce aortic root dilation rate by about 50% and are recommended as add-on or alternative therapy (Class IIa).
- ▸Long-term surveillance with annual echocardiography and blood pressure control to target <130/80 mm Hg is essential; escalate therapy or refer for surgery if aortic diameter reaches 50 mm or dilation accelerates.
After initial stabilization and acute , the cornerstone of long-term therapy in Marfan syndrome is pharmacologic reduction of aortic wall stress to slow aortic root dilation and prevent dissection. The 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease provides the framework, with beta-blockers as first-line and angiotensin receptor blockers (ARBs) as a key adjunct or alternative [1]A1c[2]A1c.
Step 1: Initiate Beta-Blocker Therapy
Beta-blockers reduce heart rate and blood pressure, lowering aortic wall stress and the rate of aortic root dilation. The ACC/AHA guideline recommends beta-blocker therapy as first-line for all patients with Marfan syndrome and aortic root dilation (Class I recommendation) [1]A1c. In a large cohort of 732 patients receiving systematic beta-blockade, the annual event rate (death or aortic dissection) was only 0.17% per year when the aortic diameter was <50 mm [33]B2b. Start with a cardioselective beta-blocker such as or and titrate to a target resting heart rate of 60 to 70 bpm and blood pressure <130/80 mm Hg. In children, beta-blockers are also first-line, with dosing adjusted for weight and heart rate response [4]A1c[8]D5.
Step 2: Add an Angiotensin Receptor Blocker
ARBs antagonize angiotensin II type 1 receptors, reducing transforming growth factor-beta (TGF-beta) signaling, a key driver of aortic wall weakness in Marfan syndrome [9]D5[27]D5. Multiple randomized trials support their efficacy:
- The COMPARE trial (n=233) found that losartan reduced aortic root dilation rate compared with no additional treatment (0.77 ± 1.36 vs 1.35 ± 1.55 mm over 3 years; P=0.014) [98]A1b.
- The LOAT trial (n=128) found no difference in aortic dilation rate between losartan and atenolol over 6.7 years, suggesting ARBs are a reasonable alternative to beta-blockers [3]B2b.
- The Marfan Sartan trial (n=303) did not show a benefit of adding losartan to background beta-blocker therapy over 3.5 years [32]A1b.
However, the individual patient data meta-analysis of seven trials (n=1442) resolved these discrepancies: allocation to an ARB approximately halved the annual rate of change in the aortic root Z score (absolute difference -0.07, 95%;), and the effect was independent of beta-blocker use [99]A1a. Long-term follow-up of the COMPARE cohort (median 8 years) demonstrated that patients who continued losartan had fewer clinical events (death, aortic dissection, elective aortic root replacement) compared with controls (composite endpoint 14 vs 26; P=0.019) [97]A1b.
The ACC/AHA guideline gives a Class IIa recommendation for ARB therapy (losartan or irbesartan) in patients with Marfan syndrome, either as an alternative to beta-blockers or as add-on therapy [1]A1c. The ESC pediatric consensus also supports ARB use in children [8]D5.
Dosing: Start at 25 to 50 mg once daily and titrate to 100 mg once daily as tolerated (50 mg if <50 kg) [32]A1b. For , start at 75 mg once daily and increase to 150 to 300 mg once daily [7]A1b. Monitor blood pressure, renal function, and potassium.
Step 3: Monitoring and Titration
- Blood pressure target: <130/80 mm Hg in adults; age-appropriate targets in children.
- Heart rate target: 60 to 70 bpm on beta-blocker.
- Imaging: Annual transthoracic echocardiography to measure aortic root diameter at the sinuses of Valsalva. If stable for 2 years, consider extending interval to 2 years [1]A1c[8]D5.
- Escalation: If aortic dilation progresses >2 mm per year or the aortic diameter approaches 50 mm (or 45-50 mm with risk factors such as family history of dissection, rapid growth, or severe ), refer for prophylactic surgical evaluation [1]A1c[33]B2b.
Step 4: Lifestyle and Long-Term Surveillance
- Exercise: Avoid isometric exercise, heavy weightlifting, and contact sports. Moderate aerobic activity (e.g., walking, swimming) is encouraged [1]A1c[8]D5. A personalized home-based exercise program improved aerobic capacity and quality of life in children without affecting aortic diameter [64]C4.
- Pregnancy: Preconception counseling is essential. Beta-blockers should be continued during pregnancy; ARBs are contraindicated in the second and third trimesters. Aortic root diameter <40 mm is associated with low risk; 40-45 mm requires close monitoring; >45 mm is a relative contraindication to pregnancy [1]A1c[16]C4.
- Avoid fluoroquinolones: These are associated with increased risk of aortic dissection in patients with Marfan syndrome and should be avoided unless no alternative exists [112]D5.
Drug Comparison Table
| Option | Mechanism | Key Trial | Effect on Aortic Root Dilation | Guideline Class |
|---|---|---|---|---|
| Beta-blocker (atenolol, propranolol) | Reduces heart rate and blood pressure | Cohort study [33]B2b | Annual event rate 0.17% with beta-blockade | Class I [1]A1c |
| ARB (losartan) | AT1 receptor blockade, reduces TGF-beta signaling | COMPARE [98]A1b, LOAT [3]B2b, Meta-analysis [99]A1a | Reduces Z score change by ~50% vs control | Class IIa [1]A1c |
| ARB (irbesartan) | Same as losartan | AIMS [7]A1b | Reduces dilation rate by 0.22 mm/year vs placebo | Class IIa [1]A1c |
| Combination (beta-blocker + ARB) | Dual pathway | COMPARE long-term [97]A1b | Reduced composite clinical events vs control | Reasonable [1]A1c |
Dosing Table
| Drug | Starting Dose | Target/Max Dose | Renal Adjustment | Hepatic Adjustment | Key Monitoring |
|---|---|---|---|---|---|
| 25 mg once daily | 50-100 mg once daily | Reduce dose if eGFR <35 mL/min | No adjustment | Heart rate, BP, ECG | |
| 20 mg twice daily | 40-160 mg twice daily | No adjustment | Reduce dose in severe hepatic impairment | Heart rate, BP, bronchospasm | |
| 25-50 mg once daily | 100 mg once daily (50 mg if <50 kg) | No adjustment; avoid if eGFR <30 mL/min | No adjustment | BP, K+, Cr | |
| 75 mg once daily | 150-300 mg once daily | No adjustment | No adjustment | BP, K+, Cr |
Treatment Failure Protocol
If aortic root dilation accelerates (>2 mm/year) or the diameter reaches 50 mm (or 45-50 mm with risk factors):
- Optimize medical therapy: ensure beta-blocker at target heart rate and ARB at maximum tolerated dose.
- Consider adding a second ARB or switching to a different ARB if not tolerated.
- Refer to a multidisciplinary aortic team for prophylactic aortic root replacement (valve-sparing or composite graft) [1]A1c[106]B2b.
What NOT to Do
- Do not use fluoroquinolones unless absolutely necessary; they increase the risk of aortic dissection [112]D5.
- Do not prescribe ARBs during pregnancy (second and third trimesters) due to fetotoxicity [1]A1c.
- Do not recommend strenuous isometric exercise or heavy weightlifting; these increase aortic wall stress [1]A1c[8]D5.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| First-line therapy: beta-blocker vs ARB | ACC/AHA 2022 recommends beta-blocker as first-line (Class I) [1]A1c | Individual patient data meta-analysis shows ARB reduces aortic root Z score by ~50%, similar to beta-blocker indirectly [99]A1a | Moderate (Class I vs emerging evidence) | Start beta-blocker first; add or switch to ARB if beta-blocker not tolerated or if aortic dilation progresses |
| Add-on ARB to beta-blocker | Marfan Sartan found no benefit of adding losartan to beta-blocker [32]A1b | COMPARE and AIMS showed benefit of ARB on top of beta-blocker [98]A1b[7]A1b; meta-analysis confirmed independent effect [99]A1a | Strong (conflicting trial results resolved by meta-analysis) | Add ARB to beta-blocker for additional aortic root protection, especially in patients with rapid dilation or high risk |
Pearl: Initiate beta-blocker therapy in all patients with Marfan syndrome and aortic root dilation; add an ARB (losartan or irbesartan) for additional aortic root protection, as supported by the individual patient data meta-analysis showing ARB reduces aortic root Z score by approximately 50% [99]A1a.
Interventional and Device Therapy
- ▸Valve-sparing root replacement (David reimplantation) is the preferred elective surgical strategy, with lower in-hospital mortality and better long-term valve durability compared to composite graft (Bentall) procedures [40,114].
- ▸In patients with mitral regurgitation grade ≤2 not undergoing concomitant mitral intervention, short-term progression is low, but long-term data are awaited [12].
- ▸AF ablation in MFS is associated with high recurrence (82.9%) and complication (28.4%) rates, requiring careful patient selection [120].
When medical therapy fails to halt progressive aortic dilation or when an acute dissection presents, surgical and transcatheter interventions become central to survival. The choice of procedure must account for the patient's age, aortic valve morphology, dissection status, and the systemic fragility of connective tissue that defines Marfan syndrome.
Aortic Root Replacement
Valve-sparing root replacement (the David reimplantation technique) is the preferred elective approach. In the largest prospective series with a median 10-year follow-up, mortality at 15 years was 6.8 ± 2.9%, and the rate of aortic insufficiency at 15 years was 7.9 ± 3.3%, lower after reimplantation than after the remodeling technique [40]B2b. A meta-analysis of 2156 patients confirmed the advantages of valve-sparing (reimplantation of the aortic valve, RAV) over composite valve graft (CVG; Bentall procedure): in‑hospital mortality OR 0.23 (95% CI 0.09-0.55), mid‑term survival 96.7% vs 86.4%, and long‑term freedom from valve‑related reintervention 97.6% vs 88.6% (IQR reported, p values from cited meta‑analysis) [114]B2a. For patients who require a Bentall procedure (e.g., irreparable valve disease), a mechanical prosthesis is favored over biological in MFS because of lower reintervention rates (reintervention for biological at 10-15 years) [66]C4.
Mitral Valve Intervention
Although the majority of MFS patients undergoing aortic root replacement also have mitral valve prolapse (MVP), only 20% require a concomitant mitral procedure [12]C4. In patients with (MR) grade ≤2 who do not undergo mitral intervention, the short‑term incidence of progressive MR is low; more follow‑up is needed to determine whether prophylactic repair benefits this subgroup [12]C4. Concomitant mitral repair or replacement does not appear to increase operative risk [12]C4.
and Dissection Risk
The long‑term risk of after isolated aortic valve replacement (without ascending replacement) is far higher in MFS than in disease: 5.5 ± 2.7% vs 0.55 ± 0.21% (p < 0.001) over a median 6.6 years [107]B2b. Thoracic aortic aneurysms and subsequent aortic surgery are similarly more frequent. This finding confirms that operative algorithms for bicuspid valve should not be extrapolated to MFS [107]B2b.
Re‑Operation After Proximal Aortic Replacement
Re‑operation occurs at a mean rate of 6.0% per person‑year in MFS, threefold higher than in patients without connective tissue disorders (2.3% per person‑year, p < 0.001), and even higher when the initial operation was for dissection (2.5% vs 1.3% per person‑year for aneurysm) [113]B2a. Pooled in‑hospital mortality for re‑operation is [113]B2a.
Percutaneous and Transcatheter Options
- Personalized external aortic root support (PEARS): mid‑term outcomes comparable to valve‑sparing root replacement (5‑year survival 98% vs 99%, freedom from ≥2/4 97% vs 92%) [115]B2b.
- Percutaneous coronary intervention for saphenous vein graft ostial stenosis after Bentall is feasible and can resolve ischemia‑driven [69]C4.
- MitraClip has been used successfully for severe mitral regurgitation after type A dissection surgery in a high‑risk surgical candidate [95]C4.
- ablation carries a high recurrence rate (82.9%) and a 28.4% complication rate (including vascular injury, pericardial effusion, phrenic nerve injury); careful patient selection and vigilant follow‑up are mandatory [120]B2b.
Mechanical Circulatory Support and Transplantation
For patients who develop after acute dissection (e.g., from coronary malperfusion), veno‑arterial ECMO with axillary artery cannulation provides antegrade flow and reduces limb ischemia risk [93]C4. Bridge‑to‑transplant with the Berlin Heart EXCOR biventricular assist device has been reported in young patients with Marfan cardiomyopathy [119]C4. Heart transplantation after acute type A dissection is reserved for those with unrecoverable left ventricular failure, as in a 14‑year‑old who required transplantation 5 days after an emergency Bentall [117]C4.
What Not to Do
- Do not treat the ascending aorta at the time of AVR using thresholds derived from bicuspid aortic valve disease; MFS patients face a substantially higher dissection risk and require more aggressive concurrent aortic replacement [107]B2b.
| Procedure | 5‑year survival | Reintervention rate | Key evidence level |
|---|---|---|---|
| Valve‑sparing root replacement (David) | 96-99% | ~2% at 15 years (valve reintervention) | 2b [40]B2b[114]B2a |
| Composite valve graft (Bentall, mechanical) | 69.5% at 10 years | 2.4% at 10 years | 4 [66]C4 |
| PEARS | 98% | No difference vs VSRR at median 25 mo | 2b [115]B2b |
Pearl: Valve‑sparing root replacement is the preferred elective procedure for aortic root aneurysm in Marfan syndrome, offering superior survival and valve durability; however, the lifelong risk of new distal aortic dissection (16.5% at 15 years [40]B2b) mandates continued imaging surveillance irrespective of the index operation.
History and Evolution of Treatment
- ▸The AIMS trial established irbesartan as the only ARB shown in a placebo-controlled trial to reduce aortic root dilatation rate in young Marfan patients [7].
- ▸Long-term COMPARE follow-up suggests a clinical benefit of combined losartan and β-blocker therapy for reducing death and aortic dissection [97].
- ▸Current guidelines endorse β-blockers as first-line therapy with ARBs as a reasonable alternative or add-on, reflecting a decade of mixed but hypothesis-generating trial evidence [1][2].
Before the adoption of composite graft repair in the 1980s, the natural history of Marfan syndrome was dominated by aortic complications with a median survival of 47 years [125]C4. The landmark 1986 series by Gott et al. changed this trajectory: elective composite valve-graft replacement at a mean aortic diameter of 7.1 cm carried a hospital mortality of only 2%, and actuarial survival at 5 years reached 87% [133]C4. However, the International Registry of Acute Aortic Dissection (IRAD) soon revealed that 59% of type A dissections occur at diameters <5.5 cm, and Marfan patients were younger (mean 32 years) and dissected at larger dimensions than non-Marfan patients [126]C4[130]C4. These observations forced a shift toward earlier prophylactic surgery and the search for effective medical therapy to slow aortic growth.
The Medical Therapy Era: Beta-Blockers to Angiotensin Receptor Blockers
Beta-blockers became the first-line medical therapy based on small observational studies demonstrating reduced aortic dilation rate and fewer aortic events. The 2022 ACC/AHA Guideline still recommends beta-blockers as initial therapy [1]A1c[2]A1c. The angiotensin-II receptor blocker (ARB) class emerged as a rational alternative after was shown to antagonize transforming growth factor-β signaling, a key pathway in Marfan aortopathy.
The ARB Trials: A Decade of Mixed Evidence
Four major randomized controlled trials shaped the evidence base:
| Trial | Drug vs. Comparator | Key Findings |
|---|---|---|
| LOAT (2018) [3]B2b | Losartan vs. (n=128, 6.7 yr) | No difference in aortic dilation rate (0.4 mm/yr in both) or composite endpoint (14.1% vs. 18.8%, p=0.462). Losartan an acceptable alternative. |
| COMPARE (2013) [98]A1b | Losartan vs. no additional therapy (n=233, 3.1 yr) | Lower aortic root dilation rate (0.77±1.36 vs. 1.35±1.55 mm, p=0.014). After prior root replacement, arch dilation also reduced. |
| COMPARE long-term (2020) [97]A1b | Losartan continued vs. control (median 8 yr) | Fewer deaths (0 vs. 5, p=0.014), fewer aortic dissections (3 vs. 11, p=0.013), composite endpoint reduced (14 vs. 26, p=0.019). |
| Marfan Sartan (2015) [32]A1b | Losartan added to β-blocker vs. placebo (n=303, 3.5 yr) | No difference in aortic root dilation (0.44 vs. 0.51 mm/yr, p=0.36). Blood pressure decreased but no effect on surgery or death. |
| AIMS (2019) [7]A1b | Irbesartan 300 mg vs. placebo (n=192, up to 5 yr, median age 18) | Reduced aortic root dilation rate (0.53 vs. 0.74 mm/yr; difference -0.22 mm/yr, p=0.030). Z-score change also reduced. |
The discrepant results highlight the importance of baseline therapy (β-blocker use in 86% of Marfan Sartan) and patient age (AIMS enrolled younger patients). The 2022 ACC/AHA Guideline concluded that ARBs are a reasonable alternative or add-on to β-blockers [1]A1c[2]A1c.
Evolving Paradigms in Pregnancy and Exercise
Pregnancy also evolved. IRAD data showed pregnancy-related type A dissection occurred only in women unaware of their diagnosis; women with prepartum aortic diameter ≤4.5 cm had stable dimensions throughout pregnancy [16]C4[23]B2b. Exercise recommendations shifted from blanket restriction toward individualized clearance for moderate-intensity activities, guided by Bethesda Conference criteria [121]D5. A recent randomized trial demonstrated that a 3‑month online structured training program improved quality of life and peak oxygen uptake without altering aortic diameter [132]A1b.
Pearl: The history of Marfan treatment is a story of incremental trial evidence, no single drug has abolished risk, but the cumulative effect of composite graft surgery, prophylactic β-blockade, and ARB therapy has extended median survival by over a decade.
| Trial | Drug | Comparator | n | Follow-up | Primary Finding |
|---|---|---|---|---|---|
| LOAT (2018) [3]B2b | Losartan | Atenolol | 128 | 6.7 yr | No difference in aortic root dilation rate (0.4 mm/yr both) |
| COMPARE (2013) [98]A1b | Losartan | No add-on | 233 | 3.1 yr | Reduced root dilation (0.77 vs 1.35 mm, p=0.014) |
| COMPARE long-term (2020) [97]A1b | Losartan | No add-on | 233 | 8 yr | Fewer deaths (0 vs 5, p=0.014) and dissections (3 vs 11, p=0.013) |
| Marfan Sartan (2015) [32]A1b | Losartan | Placebo | 303 | 3.5 yr | No difference in root dilation (0.44 vs 0.51 mm/yr, p=0.36) |
| AIMS (2019) [7]A1b | Irbesartan | Placebo | 192 | 5 yr | Reduced root dilation (0.53 vs 0.74 mm/yr, p=0.030) |
Complications
- ▸Recurrent aortic dissection is strongly associated with Marfan syndrome (HR 8.6) and is predicted by prior surgery and descending aorta diameter ≥27 mm; ARB therapy reduces risk by 70%.
- ▸Mitral annular disjunction is present in one-third of patients and is a marker for ventricular arrhythmia and the need for mitral valve surgery.
- ▸Pregnancy-related dissection risk persists for up to 1 year postpartum; beta-blocker therapy in pregnancy is associated with reduced birth weight and fetal growth restriction.
Despite advances in prophylactic aortic root replacement, patients with Marfan syndrome remain at risk for a range of cardiovascular and non-cardiovascular complications that require ongoing surveillance.
Aortic Dissection and Recurrent Dissection
Acute aortic dissection remains the most feared complication. Marfan carriers have an 8.6-fold increased risk of recurrent dissection after an initial event [10]C4. In the GenTAC registry, the 25% probability of any dissection surgery occurs at age 51 years for Marfan patients [101]B2b. Prior prophylactic aortic surgery and a proximal descending aorta diameter ≥27 mm each double the hazard for type B dissection (HR 2.2, 95% CI 1.1-4.3) [89]B2b. Angiotensin receptor blocker therapy is associated with a 70% relative risk reduction (HR 0.3, 95% CI 0.1-0.9) [89]B2b. After type A dissection repair, failure to extend surgery to the aortic root leads to >40% rate of root reintervention at 20 years [36]B2b. Patients with prior dissection also face a high need for surgery on initially untreated aortic segments, especially after type B dissection [37]B2b.
Valvular and Arrhythmic Complications
Mitral annular disjunction (MAD) is present in 34% of patients with Marfan syndrome [24]B2b. MAD >10 mm is associated with higher occurrence of aortic events (60% vs 21%; p = 0.01), and all arrhythmic events (sustained ventricular tachycardia or ) and mitral valve surgeries occurred exclusively in patients with MAD [24]B2b. Nonsustained ventricular tachycardia on Holter monitoring is more frequent in those with MAD (39% vs 17%; p = 0.01) [24]B2b. Primary cardiomyopathy with reduced LVEF is found in 25% of patients, independent of valvular disease [20]C4.
Non-Cardiovascular Complications
Spontaneous pneumothorax can be a presenting or recurrent complication due to bleb formation and distal acinar emphysema [26]D5[148]C4. Ocular complications include ectopia lentis, early cataract, glaucoma, and , with retinal detachment risk heightened after lens removal [48]B2b[146]D5. Cervical spine instability and deformity may occur but often remain asymptomatic [31]D5.
Complications of Therapy
Beta-blocker use in pregnancy is associated with a mean 442 g lower birth weight and higher rates of fetal growth restriction and neonatal bradycardia [47]B2b. Redo sternotomy is common (41% of operated patients), independently predicted by (OR 2.39), emergent initial operation (OR 3.38), and postoperative complications (OR 2.59) [21]B2b.
| Complication | Approximate Frequency | Prevention | |
|---|---|---|---|
| Recurrent aortic dissection | HR 8.6 vs non-Marfan [10]C4 | β-blocker ± ARB; elective root replacement; ARB for type B risk reduction [89]B2b | Emergent surgical repair per type; long-term imaging surveillance |
| Type B dissection after prior surgery | 10-yr risk 34% in high-risk [89]B2b | Descending aorta monitoring; ARB therapy | TEVAR or open repair; strict BP control |
| Mitral annular disjunction with arrhythmia | 34% prevalence of MAD; 39% with MAD have NSVT [24]B2b | Echocardiographic screening for MAD | Holter monitoring; electrophysiology referral for sustained VT |
| Redo sternotomy | 41% of operated patients [21]B2b | Root replacement at initial surgery; BP control | Careful preoperative planning; multidisciplinary team |
| Pregnancy-related aortic dissection | 5-fold vs non-pregnant [16]C4; 1.8-2.7% perinatal period [147]B2b | Pre-pregnancy aortic diameter ≤4.0 cm; β-blocker continuation | Urgent surgical repair; postpartum monitoring for 1 year [147]B2b |
| Spontaneous pneumothorax | Not systematically reported | Smoking avoidance; pulmonary surveillance | Chest tube drainage ± pleurodesis; consider bleb resection [148]C4 |
| Ocular complications | Ectopia lentis in ~60% [48]B2b; retinal detachment risk after lens removal | Yearly ophthalmologic exam; complete capsular removal during lens surgery [146]D5 | Lens extraction with capsular support devices; retinal detachment repair |
Pearl: Mitral annular disjunction >10 mm identifies patients at highest risk for aortic events and ventricular arrhythmia, warranting intensified aortic surveillance and a low threshold for Holter monitoring [24]B2b.
Prognosis and Natural History
- ▸Untreated Marfan syndrome carries a mean life expectancy of 32 years; contemporary care reduces annual event rates to 0.17%/year overall.
- ▸Prophylactic aortic root replacement at 50 mm is standard; valve-sparing root replacement offers better survival than conservative approaches.
- ▸Haploinsufficient FBN1 mutations, vertebral tortuosity index ≥50, family history of dissection, and aortic branch aneurysms independently predict worse outcomes.
The complications outlined above, aortic dissection, sudden death, and progressive aortic dilation, define the natural history of Marfan syndrome. Before prophylactic surgery, mean life expectancy was 32 years; with contemporary care, the annual event rate (death or dissection) is 0.17%/year overall, rising to 1.33%/year at aortic diameters of 50-54 mm [33]B2b. Risk of type A dissection remains low at diameters <50 mm (0.4 events/1,000 patient-years) [39]B2b.
β-blockers remain standard first-line therapy, though a meta-analysis found no significant reduction in aortic events (RR 0.74, 95% CI 0.20-2.71; low certainty) [46]A1a. ARBs show a statistically significant but clinically uncertain effect on aortic growth [151]D5. Prophylactic aortic root replacement at 50 mm yields excellent outcomes; valve-sparing root replacement is associated with better survival than conservative root approaches (HR 0.74, 95%) [45]B2a. After type A dissection, failure to replace the root leads to >40% reintervention at 20 years [36]B2b.
Several predictors refine risk beyond diameter (Table 1). Haploinsufficient FBN1 mutations confer a 2.5-fold increased risk of cardiovascular death (HR 2.5, 95%) [150]B2b. Vertebral tortuosity index ≥50 predicts earlier dissection and death [76]B2b. Family history of dissection increases risk 6.8-fold [41]B2b. Aortic branch aneurysms (27% of patients) independently predict need for surgery (HR 3.4) [15]B2b.
Table 1. Validated Predictors of Adverse Aortic Events
| Predictor | Measure | Risk Increase |
|---|---|---|
| FBN1 haploinsufficiency | HI vs DN | HR 2.5 for CV death [150]B2b |
| Vertebral tortuosity index | VTI ≥50 | Earlier dissection/death [76]B2b |
| Family history of dissection | First-degree relative | RR 6.82 [41]B2b |
| Aortic branch aneurysms | Present on imaging | HR 3.4 for surgery [15]B2b |
Pearl: In Marfan syndrome, the risk of aortic dissection is low when the aortic root diameter is <50 mm under guideline-directed therapy, but genotype (haploinsufficiency), vertebral tortuosity, and family history identify a higher-risk subset that may warrant earlier surgical intervention or more frequent surveillance.
Special Populations and Prevention
- ▸Continue beta-blockers during pregnancy despite a 442 g reduction in birth weight; maternal survival benefit outweighs the fetal growth effect [47].
- ▸In women aware of their Marfan diagnosis, prophylactic counseling and surveillance eliminate type A aortic dissection during pregnancy, but type B dissections remain unpredictable [16].
- ▸Pediatric management requires growth-adjusted aortic z‑scores and tailored activity restrictions; moderate aerobic exercise is safe [88][157].
Prognosis in Marfan syndrome is dominated by aortic risk, but this risk shifts across the lifespan and is modified by growth, pregnancy, activity, and aging. must be tailored to special populations, with prevention strategies applied from diagnosis.
Pediatrics
Diagnosis in childhood requires with aortic dimensions indexed to body surface area using z‑scores, as absolute thresholds do not apply. Beta‑blocker therapy, typically or , is first‑line to slow aortic root growth and reduce dissection risk [88]D5. Angiotensin receptor blockers (e.g., ) are added as second‑line therapy. Surveillance echocardiography is performed annually; intervals shorten to every 6 months if the aortic z‑score exceeds 3 or rapid dilation occurs [88]D5. Competitive sports with static/isometric demands are restricted; moderate aerobic activity (e.g., swimming, cycling) is encouraged [88]D5[157]D5. Prophylactic aortic root replacement is considered when the aortic diameter reaches 5.0 cm in adolescents or earlier if growth accelerates or family history of early dissection exists.
Pregnancy
Preconception counseling is mandatory and should involve a multidisciplinary aortopathy team [1]A1c[2]A1c[152]A1c. Pregnancy is considered safe when the prepartum aortic root diameter is <4.5 cm and remains stable; those with diameters 4.0-4.5 cm show stable dimensions during gestation [16]C4. Beta‑blockers (e.g., , ) are continued to reduce aortic shear stress, but they are associated with a 442 g lower mean birth weight and higher rates of fetal growth restriction and neonatal bradycardia (NNT for harm not calculable from reported data) [47]B2b. Continue beta‑blockers regardless, the maternal survival benefit outweighs the fetal growth effect. Serial echocardiography is performed every 4-8 weeks [155]D5. Delivery is typically by when the aortic root exceeds 4.0 cm or if there is rapid dilation; vaginal delivery with epidural anesthesia and a shortened second stage is an option for lower‑risk women [155]D5. Postpartum surveillance is critical: 2.7% of women experienced dissection during postpartum hospitalization and 2.7% were re‑hospitalized for dissection within one year [147]B2b. Type A dissection occurred only in women unaware of their diagnosis; type B dissection remains an unpredictable complication [16]C4. for lactation suppression did not significantly alter dissection risk [147]B2b. Dissection risk persists for at least 12 weeks postpartum [23]B2b.
Elderly
Aortic risk is compounded by age‑related and reduced aortic compliance. Blood pressure should be rigorously controlled to a target <120/80 mm Hg. Surgical thresholds for prophylactic aortic replacement remain the same (≥5.0 cm root or ascending aorta), but operative risk is higher, requiring careful frailty assessment [154]D5. Comorbidities such as , for which Marfan syndrome itself is a risk factor [44]D5, and osteoporosis may complicate management. Surveillance intervals may be extended to every 2-3 years if the aortic diameter is stable and <4.5 cm.
Athletes and Physical Activity
All patients with Marfan syndrome should undergo pre‑participation cardiovascular screening including echocardiography. Competitive sports involving high static/isometric loads (e.g., weightlifting, wrestling) are contraindicated in the presence of aortic dilation or a family history of dissection [88]D5[157]D5. Moderate aerobic exercise (e.g., jogging, tennis, swimming) is safe for most patients and benefits cardiovascular fitness. is common in Marfan syndrome and can cause cardiac compression, reduced stroke volume during exercise, and ECG changes (right bundle branch block, T‑wave inversion) that mimic cardiomyopathy [157]D5. Shared decision‑making between the athlete, cardiologist, and sports medicine specialist is essential.
Prevention
Primary prevention begins with early diagnosis, cascade family screening, and genetic counseling. Lifelong beta‑blocker therapy is recommended regardless of aortic diameter to slow aortic growth [88]D5. Angiotensin receptor blockers are added, especially in patients with a rapid growth rate. Blood pressure targets are <120/80 mm Hg. Smoking, use, and strenuous lifting are avoided. Secondary prevention after prophylactic aortic root replacement or prior dissection focuses on strict blood pressure control, serial imaging of the remaining aorta, and maintenance of beta‑blocker/ARB therapy.
Pearl: Pediatric management requires growth-adjusted aortic z‑scores and tailored activity restrictions; moderate aerobic exercise is safe [88]D5[157]D5.
References
- [1]
Isselbacher EM, Preventza O, Hamilton Black J et al.. “2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.” Circulation (2022). PMID: 36322642 ↗
L1GUIDELINECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Special Populations and Prevention - [2]
Isselbacher EM, Preventza O, Hamilton Black Iii J et al.. “2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2022). PMID: 36334952 ↗
L1GUIDELINECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Special Populations and Prevention - [3]
Teixido-Tura G, Forteza A, Rodríguez-Palomares J et al.. “Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome.” Journal of the American College of Cardiology (2018). PMID: 30261963 ↗
L2RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History - [4]
Morris SA, Flyer JN, Yetman AT et al.. “Cardiovascular Management of Aortopathy in Children: A Scientific Statement From the American Heart Association.” Circulation (2024). PMID: 39129620 ↗
L1REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy - [5]
Fletcher AJ, Syed MBJ, Aitman TJ et al.. “Inherited Thoracic Aortic Disease: New Insights and Translational Targets.” Circulation (2020). PMID: 32392100 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy - [6]
Goldfinger JZ, Halperin JL, Marin ML et al.. “Thoracic aortic aneurysm and dissection.” Journal of the American College of Cardiology (2014). PMID: 25323262 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy - [7]
Mullen M, Jin XY, Child A et al.. “Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial.” Lancet (London, England) (2019). PMID: 31836196 ↗
L1RCTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [8]
Muiño-Mosquera L, Cervi E, De Groote K et al.. “Management of aortic disease in children with FBN1-related Marfan syndrome.” European heart journal (2024). PMID: 39250726 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications - [9]
Matt P, Schoenhoff F, Habashi J et al.. “Circulating transforming growth factor-beta in Marfan syndrome.” Circulation (2009). PMID: 19635970 ↗
L5OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy - [10]
Isselbacher EM, Bonaca MP, Di Eusanio M et al.. “Recurrent Aortic Dissection: Observations From the International Registry of Aortic Dissection.” Circulation (2016). PMID: 27587434 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, History and Evolution of Treatment, Complications, Prognosis and Natural History - [11]
Attias D, Stheneur C, Roy C et al.. “Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders.” Circulation (2009). PMID: 19996017 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History - [12]
Kunkala MR, Schaff HV, Li Z et al.. “Mitral valve disease in patients with Marfan syndrome undergoing aortic root replacement.” Circulation (2013). PMID: 24030414 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Interventional and Device Therapy - [13]
Evangelista A, Salas A, Ribera A et al.. “Long-term outcome of aortic dissection with patent false lumen: predictive role of entry tear size and location.” Circulation (2012). PMID: 22615344 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, History and Evolution of Treatment, Complications, Prognosis and Natural History - [14]
Calderon-Martinez E, Velasco WV, Guo D et al.. “Differences in Arterial Events in Vascular Ehlers-Danlos, Loeys-Dietz, and Marfan Syndrome.” Journal of the American College of Cardiology (2025). PMID: 40533124 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Complications - [15]
Lopez-Sainz A, Mila L, Rodriguez-Palomares J et al.. “Aortic Branch Aneurysms and Vascular Risk in Patients With Marfan Syndrome.” Journal of the American College of Cardiology (2021). PMID: 34140103 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History - [16]
Narula N, Devereux RB, Malonga GP et al.. “Pregnancy-Related Aortic Complications in Women With Marfan Syndrome.” Journal of the American College of Cardiology (2021). PMID: 34446158 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Special Populations and Prevention - [17]
Giuliani L, Di Toro A, Urtis M et al.. “Prevalence and Complications of Aberrant Subclavian Artery in Patients With Heritable and Nonheritable Arteriopathies.” Journal of the American College of Cardiology (2023). PMID: 36889877 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Complications - [18]
David TE, Park J, Tatangelo M et al.. “Cardiovascular Events After Aortic Root Repair in Patients With Marfan Syndrome.” Journal of the American College of Cardiology (2023). PMID: 37673508 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Complications - [19]
Guala A, Teixidó-Tura G, Rodríguez-Palomares J et al.. “Proximal aorta longitudinal strain predicts aortic root dilation rate and aortic events in Marfan syndrome.” European heart journal (2019). PMID: 30977783 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Complications, Prognosis and Natural History - [20]
Alpendurada F, Wong J, Kiotsekoglou A et al.. “Evidence for Marfan cardiomyopathy.” European journal of heart failure (2010). PMID: 20861133 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment, Complications, Prognosis and Natural History - [21]
Abdul Nabi H, Dreher LA, Kanaan C et al.. “Cardiac surgical outcomes and predictors of redo sternotomy in patients with Marfan syndrome: a retrospective multicentre cohort study.” Open heart (2026). PMID: 42229999 ↗
L2COHORTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Complications - [22]
Jia WN, Chen ZX, Shen X et al.. “Clinical and Surgical Implications of Genotype-Phenotype Correlations in Congenital Ectopia Lentis: A Real-World Cohort Study.” Investigative ophthalmology & visual science (2026). PMID: 42126156 ↗
L4COHORTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management - [23]
Braverman AC, Mittauer E, Harris KM et al.. “Clinical Features and Outcomes of Pregnancy-Related Acute Aortic Dissection.” JAMA cardiology (2021). PMID: 33052376 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Special Populations and Prevention - [24]
Demolder A, Timmermans F, Duytschaever M et al.. “Association of Mitral Annular Disjunction With Cardiovascular Outcomes Among Patients With Marfan Syndrome.” JAMA cardiology (2021). PMID: 34232254 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Complications - [25]
Yang Y, Muzny DM, Xia F et al.. “Molecular findings among patients referred for clinical whole-exome sequencing.” JAMA (2014). PMID: 25326635 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy - [26]
Chen X, Ryu JH, Hu X. “Spontaneous pneumothorax-associated with genetic disorders.” Therapeutic advances in respiratory disease (2026). PMID: 41905781 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History - [27]
Maciel Oliveira G, Junqueira Franco Stoppe J, Duarte de Andrade SM et al.. “What's new about angiotensin receptor blocker (ARB) therapy for Marfan syndrome: A narrative review.” Vascular medicine (London, England) (2026). PMID: 41631533 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Long-term Guideline-Directed Therapy - [28]
Abdul-Rahman T, Roy P, Garg N et al.. “Gene editing for inherited cardiac conditions: A new frontier in cardiology.” Trends in cardiovascular medicine (2025). PMID: 41237872 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation - [29]
Jayaratne N, Gianni A, Riding N et al.. “Exercise recommendations for patients with Marfan syndrome: an updated review.” European journal of preventive cardiology (2026). PMID: 41152210 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Complications, Prognosis and Natural History - [30]
Autret L, Shipley É, Lodde B et al.. “Rheumatic and musculoskeletal disorders in musicians: risks, adaptations and management.” RMD open (2025). PMID: 41083266 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, History and Evolution of Treatment - [31]
Vialle R. “Pathologies of the cervical spine in skeletal syndromes and dysplasias.” Orthopaedics & traumatology, surgery & research : OTSR (2025). PMID: 40976314 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Complications - [32]
Milleron O, Arnoult F, Ropers J et al.. “Marfan Sartan: a randomized, double-blind, placebo-controlled trial.” European heart journal (2015). PMID: 25935877 ↗
L1RCTCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History - [33]
Jondeau G, Detaint D, Tubach F et al.. “Aortic event rate in the Marfan population: a cohort study.” Circulation (2011). PMID: 22133496 ↗
L2COHORTCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History - [34]
Isselbacher EM, Lino Cardenas CL, Lindsay ME. “Hereditary Influence in Thoracic Aortic Aneurysm and Dissection.” Circulation (2016). PMID: 27297344 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism - [35]
Raunsø J, Song RJ, Vasan RS et al.. “Familial Clustering of Aortic Size, Aneurysms, and Dissections in the Community.” Circulation (2020). PMID: 32580567 ↗
L2OTHERCited in: Epidemiology and Risk Factors - [36]
Rylski B, Bavaria JE, Beyersdorf F et al.. “Type A aortic dissection in Marfan syndrome: extent of initial surgery determines long-term outcome.” Circulation (2014). PMID: 24594630 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Complications, Prognosis and Natural History - [37]
Schoenhoff FS, Jungi S, Czerny M et al.. “Acute aortic dissection determines the fate of initially untreated aortic segments in Marfan syndrome.” Circulation (2013). PMID: 23493319 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Clinical Presentation, Acute and Initial Management, Complications - [38]
Narula N, Devereux RB, Arbustini E et al.. “Risk of Type B Dissection in Marfan Syndrome: The Cornell Aortic Aneurysm Registry.” Journal of the American College of Cardiology (2023). PMID: 37930285 ↗
L3OTHERCited in: Epidemiology and Risk Factors, History and Evolution of Treatment - [39]
Milleron O, Arnoult F, Delorme G et al.. “Pathogenic FBN1 Genetic Variation and Aortic Dissection in Patients With Marfan Syndrome.” Journal of the American College of Cardiology (2020). PMID: 32130918 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Acute and Initial Management, History and Evolution of Treatment, Complications, Prognosis and Natural History - [40]
David TE, David CM, Manlhiot C et al.. “Outcomes of Aortic Valve-Sparing Operations in Marfan Syndrome.” Journal of the American College of Cardiology (2015). PMID: 26403341 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Interventional and Device Therapy, Prognosis and Natural History - [41]
Chen SW, Kuo CF, Huang YT et al.. “Association of Family History With Incidence and Outcomes of Aortic Dissection.” Journal of the American College of Cardiology (2020). PMID: 32883411 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, History and Evolution of Treatment, Prognosis and Natural History - [42]
Détaint D, Faivre L, Collod-Beroud G et al.. “Cardiovascular manifestations in men and women carrying a FBN1 mutation.” European heart journal (2010). PMID: 20709720 ↗
L2OTHERCited in: Epidemiology and Risk Factors - [43]
Henry M, Campello Jorge CA, van Bakel PAJ et al.. “Thoracic Aortic Aneurysm Growth Rates and Predicting Factors: A Systematic Review and Meta-Analysis.” Journal of the American Heart Association (2025). PMID: 40145320 ↗
L2SR_OBSCited in: Epidemiology and Risk Factors - [44]
Brown RF, Lopez K, Smith CB et al.. “Diverticulitis: A Review.” JAMA (2025). PMID: 40705318 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Special Populations and Prevention - [45]
Zhang Y, Lin H, Li Y et al.. “Aortic root replacement versus preservation in acute type A aortic dissection repair: meta-analysis of reconstructed time-to-event data.” Journal of cardiothoracic surgery (2025). PMID: 41353548 ↗
L2SR_OBSCited in: Epidemiology and Risk Factors, Acute and Initial Management, Prognosis and Natural History - [46]
Tanriverdi LH, Barrett A, Kalyanasundaram A et al.. “Efficacy of beta-blocker agents on clinical outcomes in patients with thoracic aortic aneurysm: A systematic review and meta-analysis of randomized controlled trials.” Vascular pharmacology (2025). PMID: 40204023 ↗
L1SR_MA_RCTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Prognosis and Natural History - [47]
Grégori M, Le Gloan L, Goronflot T et al.. “Impact of β-Blockers on the Risk of Low-Birth-Weight Infants in Women with Long QT Syndrome or Marfan Syndrome: A Single-Center Retrospective Study from 2008 to 2022 in a Tertiary Care Center.” Paediatric drugs (2026). PMID: 41653364 ↗
L2COHORTCited in: Epidemiology and Risk Factors, Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Special Populations and Prevention - [48]
Shen X, Chen Z, Jia W et al.. “Phenotype-driven clustering of ocular manifestations reveals prognostic and genetic heterogeneity in Marfan syndrome: a real-world longitudinal cohort study.” Journal of translational medicine (2025). PMID: 41331757 ↗
L2COHORTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History - [49]
Bin Helayel H, Magliyah MS, Alnutaifi R et al.. “Surgical Outcomes of Lens Removal with or Without Intraocular Lens Implantation in Marfan Syndrome: A Retrospective Cohort Study.” Clinical ophthalmology (Auckland, N.Z.) (2025). PMID: 41282459 ↗
L2COHORTCited in: Epidemiology and Risk Factors, Clinical Presentation, Prognosis and Natural History - [50]
Nagata K, Taniguchi Y, Nakajima K et al.. “Bone mineral density in pediatric Marfan syndrome patients with scoliosis: a retrospective case-control study using hounsfield units.” European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society (2026). PMID: 41894045 ↗
L3CASE_CONTROLCited in: Epidemiology and Risk Factors - [51]
Yetman AT, Graham T. “The dilated aorta in patients with congenital cardiac defects.” Journal of the American College of Cardiology (2009). PMID: 19195601 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism - [52]
Hofmann Bowman MA, Eagle KA, Milewicz DM. “Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review.” JAMA cardiology (2019). PMID: 31066871 ↗
L5TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Acute and Initial Management, Complications - [53]
Oller J, Gabandé-Rodríguez E, Ruiz-Rodríguez MJ et al.. “Extracellular Tuning of Mitochondrial Respiration Leads to Aortic Aneurysm.” Circulation (2021). PMID: 33709773 ↗
L5OTHERCited in: Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy - [54]
Kim AJ, Xu N, Umeyama K et al.. “Deficiency of Circulating Monocytes Ameliorates the Progression of Myxomatous Valve Degeneration in Marfan Syndrome.” Circulation (2020). PMID: 31928435 ↗
L5OTHERCited in: Pathophysiology and Mechanism, Complications - [55]
Heegaard AM, Corsi A, Danielsen CC et al.. “Biglycan deficiency causes spontaneous aortic dissection and rupture in mice.” Circulation (2007). PMID: 17502576 ↗
L5OTHERCited in: Pathophysiology and Mechanism - [56]
Ikonomidis JS, Jones JA, Barbour JR et al.. “Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome.” Circulation (2006). PMID: 16820601 ↗
L3OTHERCited in: Pathophysiology and Mechanism, Acute and Initial Management, Complications - [57]
Zheng J, Chen Y, Pat B et al.. “Microarray identifies extensive downregulation of noncollagen extracellular matrix and profibrotic growth factor genes in chronic isolated mitral regurgitation in the dog.” Circulation (2009). PMID: 19349319 ↗
L5OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation - [58]
Guo G, Booms P, Halushka M et al.. “Induction of macrophage chemotaxis by aortic extracts of the mgR Marfan mouse model and a GxxPG-containing fibrillin-1 fragment.” Circulation (2006). PMID: 17030689 ↗
L5OTHERCited in: Pathophysiology and Mechanism - [59]
Geirsson A, Singh M, Ali R et al.. “Modulation of transforming growth factor-β signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers.” Circulation (2012). PMID: 22965982 ↗
L3OTHERCited in: Pathophysiology and Mechanism - [60]
Roberts WC, Vowels TJ, Ko JM et al.. “Comparison of the structure of the aortic valve and ascending aorta in adults having aortic valve replacement for aortic stenosis versus for pure aortic regurgitation and resection of the ascending aorta for aneurysm.” Circulation (2011). PMID: 21321157 ↗
L4OTHERCited in: Pathophysiology and Mechanism - [61]
Roberts WC, Ko JM, Moore TR et al.. “Causes of pure aortic regurgitation in patients having isolated aortic valve replacement at a single US tertiary hospital (1993 to 2005).” Circulation (2006). PMID: 16864725 ↗
L4OTHERCited in: Pathophysiology and Mechanism - [62]
Donnelly RT, Pinto NM, Kocolas I et al.. “The immediate and long-term impact of pregnancy on aortic growth rate and mortality in women with Marfan syndrome.” Journal of the American College of Cardiology (2012). PMID: 22789886 ↗
L3OTHERCited in: Pathophysiology and Mechanism, Prognosis and Natural History, Special Populations and Prevention - [63]
Rochano-Ortiz A, San Sebastián-Jaraba I, Zamora C et al.. “Excessive glycosylation drives thoracic aortic aneurysm formation through integrated stress response.” European heart journal (2025). PMID: 40720766 ↗
L5OTHERCited in: Pathophysiology and Mechanism, Complications - [64]
Edouard T, Bajanca F, Flumian C et al.. “A personalized home-based exercise training program in children with Marfan and Loeys-Dietz syndromes improves aerobic exercise capacity and health-related quality of life.” Orphanet journal of rare diseases (2026). PMID: 41639855 ↗
L4TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy - [65]
Krych S, Gniewek J, Jurkiewicz M et al.. “Aortopathy in Bicuspid Aortic Valve: Pathophysiology, Risk Stratification and Surgical Decision-Making-A Narrative Review.” Journal of clinical medicine (2026). PMID: 42123275 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Clinical Presentation, Severity Staging and Risk Stratification, Prognosis and Natural History - [66]
Murana G, Di Marco L, Zanella L et al.. “Bentall Procedure: A Long-term, Single Center Experience.” Seminars in thoracic and cardiovascular surgery (2025). PMID: 40614792 ↗
L4REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Interventional and Device Therapy - [67]
Santos AR, Gutierrez RMS, Koike TE et al.. “Skeletal muscle alterations in Marfan syndrome: a systematic review.” Journal of muscle research and cell motility (2025). PMID: 40833584 ↗
L2SR_OBSCited in: Pathophysiology and Mechanism - [68]
Shalhub S. “The aortic and arterial vulnerability spectrum: A conceptual biological framework for risk stratification and precision surgical decision-making in aortopathy and arteriopathy.” Journal of vascular surgery (2025). PMID: 40471774 ↗
L5CASE_REPORTCited in: Pathophysiology and Mechanism, Severity Staging and Risk Stratification, History and Evolution of Treatment - [69]
Tokuno S, Takeuchi T, Nakagawa N. “Revascularization of a Saphenous Vein Graft Ostial Stenosis in a Patient With Marfan Syndrome and a Previous Bentall Procedure Who was Resuscitated From Ventricular Fibrillation.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 40468704 ↗
L4CASE_REPORTCited in: Pathophysiology and Mechanism, Interventional and Device Therapy - [70]
Wang X, Tan Q, Xu J et al.. “Genetic and molecular mechanisms of hereditary thoracic aortic aneurysm and dissection (Review).” Molecular medicine reports (2026). PMID: 42318957 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism - [71]
Vereckei A, Jenei Z, Vágó H et al.. “Mitral Annular Calcification, a Not So Marginal and Relatively Benign Finding as Many of Us Think: A Review.” Journal of cardiovascular development and disease (2025). PMID: 40558667 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism - [72]
Parks CA, Singh M, Wohler E et al.. “Spontaneous spinal CSF leaks: a rare variant exome sequencing study and functional analysis.” The Lancet. Neurology (2026). PMID: 42309087 ↗
L3OTHERCited in: Pathophysiology and Mechanism - [73]
Sherrah AG, Andvik S, van der Linde D et al.. “Nonsyndromic Thoracic Aortic Aneurysm and Dissection: Outcomes With Marfan Syndrome Versus Bicuspid Aortic Valve Aneurysm.” Journal of the American College of Cardiology (2016). PMID: 26868685 ↗
L2OTHERCited in: Clinical Presentation, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History - [74]
Korukonda S, Byers PH, Kovuri P et al.. “Genotype-aortic phenotype correlations in Marfan syndrome: a systematic review and meta-analysis of Fibrillin-1 variants.” Heart (British Cardiac Society) (2025). PMID: 41309212 ↗
L1SR_OBSCited in: Clinical Presentation, Complications, Prognosis and Natural History - [75]
Dong ZH, Fu WG, Wang YQ et al.. “Retrograde type A aortic dissection after endovascular stent graft placement for treatment of type B dissection.” Circulation (2009). PMID: 19171859 ↗
L4OTHERCited in: Diagnosis and Workup, Complications - [76]
Morris SA, Orbach DB, Geva T et al.. “Increased vertebral artery tortuosity index is associated with adverse outcomes in children and young adults with connective tissue disorders.” Circulation (2011). PMID: 21730308 ↗
L2OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History - [77]
Song JM, Kim SD, Kim JH et al.. “Long-term predictors of descending aorta aneurysmal change in patients with aortic dissection.” Journal of the American College of Cardiology (2007). PMID: 17707186 ↗
L2OTHERCited in: Diagnosis and Workup, Prognosis and Natural History - [78]
Guo S, Wang Z, Zhang N et al.. “Transcatheter closure of paravalvular leak after Bentall surgery in a Marfan patient: a rare case report.” Frontiers in cardiovascular medicine (2026). PMID: 41623879 ↗
L4CASE_REPORTCited in: Diagnosis and Workup - [79]
Yokouchi-Konishi T, Aoki-Kamiya C, Tsuritani M et al.. “The impact of FBN1 variant types on pregnancy-related aortic dissection in women with Marfan syndrome.” International journal of cardiology (2026). PMID: 42314848 ↗
L2OTHERCited in: Diagnosis and Workup, Long-term Guideline-Directed Therapy - [80]
Umei M, Diller GP, Brida M et al.. “Distribution, recognition and clinical implications of syndromic conditions in adults with congenital heart disease.” Open heart (2026). PMID: 42020136 ↗
L2OTHERCited in: Diagnosis and Workup - [81]
Bosshardt D, Merton R, Nederveen AJ et al.. “Aortic displacement and hemodynamics are abnormal in patients with Marfan syndrome: A combined four-dimensional balanced steady-state free precession and four-dimensional flow cardiac magnetic resonance study.” Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance (2026). PMID: 42019568 ↗
L3OTHERCited in: Diagnosis and Workup, History and Evolution of Treatment - [82]
Narula N, Devereux RB, Ma X et al.. “Outcomes of Type B Dissection in Marfan Syndrome: The Cornell Aortic Aneurysm Registry.” Journal of the American Heart Association (2026). PMID: 42017320 ↗
L2OTHERCited in: Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy - [83]
Bosshardt D, Merton R, Schrauben EM et al.. “Assessing changes in aortic motion and hemodynamics after valve-sparing aortic root surgery in Marfan syndrome using four-dimensional balanced steady-state free precession and four-dimensional flow cardiovascular magnetic resonance.” Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance (2026). PMID: 42001956 ↗
L4OTHERCited in: Diagnosis and Workup, Acute and Initial Management - [84]
Bhutada S, Martin DR, Cikach F et al.. “Integrated Forward and Reverse Degradomics of Aortic Aneurysms Uncovers Their Proteolytic Landscapes and the Roles of MMP9 and Mast Cell Chymase.” Arteriosclerosis, thrombosis, and vascular biology (2026). PMID: 41924878 ↗
L5OTHERCited in: Diagnosis and Workup - [85]
Grewal N, Niessen HWM. “Beyond the tear: the enduring role of aortic pathology in the era of genomic medicine.” Open heart (2026). PMID: 41856676 ↗
L5OTHERCited in: Diagnosis and Workup, Acute and Initial Management - [86]
Dwivedi KK, Wu Y, Bazzi MS et al.. “Alterations in ascending aortic hemodynamics and aortic length correlate with sex-specific thoracic aortic aneurysm dilation and lifespan in a mouse model of severe Marfan syndrome.” Computers in biology and medicine (2026). PMID: 41775185 ↗
L5OTHERCited in: Diagnosis and Workup, Long-term Guideline-Directed Therapy - [87]
Tournoy TK, D'hulst S, Demolder A et al.. “Telomere length in patients with Marfan Syndrome.” International journal of cardiology (2026). PMID: 41679654 ↗
L3OTHERCited in: Diagnosis and Workup - [88]
De Backer JFA, Muino Mosquera L, Rodriguez-Palomares JF et al.. “Diagnosis and management of heritable thoracic aortic diseases.” Heart (British Cardiac Society) (2026). PMID: 41638893 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Long-term Guideline-Directed Therapy, Special Populations and Prevention - [89]
den Hartog AW, Franken R, Zwinderman AH et al.. “The risk for type B aortic dissection in Marfan syndrome.” Journal of the American College of Cardiology (2015). PMID: 25614422 ↗
L2OTHERCited in: Severity Staging and Risk Stratification, Acute and Initial Management, Complications - [90]
Kawashima Y, Takeda N, Omori A et al.. “Genotype-Guided Risk Stratification of Mitral Valve Surgery in Marfan Syndrome.” Journal of the American College of Cardiology (2026). PMID: 41811274 ↗
L2OTHERCited in: Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy - [91]
Soto ME, Ochoa-Hein E, Anaya-Ayala JE et al.. “Systematic review and meta-analysis of aortic valve-sparing surgery versus replacement surgery in ascending aortic aneurysms and dissection in patients with Marfan syndrome and other genetic connective tissue disorders.” Journal of thoracic disease (2021). PMID: 34527322 ↗
L2SR_OBSCited in: Severity Staging and Risk Stratification - [92]
Zhu QY, Lv XS, Li SM et al.. “Prognostic analysis of acute type A aortic dissection after different surgical interventions: a cohort study.” Journal of thoracic disease (2024). PMID: 39831215 ↗
L2COHORTCited in: Severity Staging and Risk Stratification - [93]
Qiu F, Luo L, Huang J et al.. “Case Report: Improved axillary artery cannulation and extracorporeal membrane oxygenation bridging therapy for cardiogenic shock caused by Marfan syndrome combined with aortic dissection.” Frontiers in cardiovascular medicine (2026). PMID: 41908050 ↗
L4CASE_REPORTCited in: Severity Staging and Risk Stratification, Acute and Initial Management, Interventional and Device Therapy, History and Evolution of Treatment - [94]
Pugnaloni F, De Rose DU, Digilio MC et al.. “Neonatal Marfan syndrome: a case report of a novel fibrillin 1 mutation, with genotype-phenotype correlation and brief review of the literature.” Italian journal of pediatrics (2024). PMID: 39294662 ↗
L4CASE_REPORTCited in: Severity Staging and Risk Stratification - [95]
Wang C, Wang G, Lu W et al.. “MitraClip used for severe mitral regurgitation after surgery for type A aortic dissection combined with Marfan syndrome.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2023). PMID: 37526225 ↗
L4CASE_REPORTCited in: Severity Staging and Risk Stratification, Interventional and Device Therapy - [96]
Kawamura I, Yamaguchi T, Yanagida H et al.. “Factors contributing to severe scoliosis after open chest surgery for congenital heart disease: a case-control analysis.” Spine deformity (2024). PMID: 39531160 ↗
L3CASE_CONTROLCited in: Severity Staging and Risk Stratification - [97]
van Andel MM, Indrakusuma R, Jalalzadeh H et al.. “Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial.” European heart journal (2020). PMID: 32548624 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [98]
Groenink M, den Hartog AW, Franken R et al.. “Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial.” European heart journal (2013). PMID: 23999449 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [99]
Pitcher A, Spata E, Emberson J et al.. “Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.” Lancet (London, England) (2022). PMID: 36049495 ↗
L1SR_OBSCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications - [100]
Nataatmadja M, West J, West M. “Overexpression of transforming growth factor-beta is associated with increased hyaluronan content and impairment of repair in Marfan syndrome aortic aneurysm.” Circulation (2006). PMID: 16820603 ↗
L5OTHERCited in: Acute and Initial Management, Complications - [101]
Holmes KW, Markwardt S, Eagle KA et al.. “Cardiovascular Outcomes in Aortopathy: GenTAC Registry of Genetically Triggered Aortic Aneurysms and Related Conditions.” Journal of the American College of Cardiology (2022). PMID: 35618343 ↗
L2OTHERCited in: Acute and Initial Management, Complications - [102]
Mimoun L, Detaint D, Hamroun D et al.. “Dissection in Marfan syndrome: the importance of the descending aorta.” European heart journal (2010). PMID: 21147864 ↗
L2OTHERCited in: Acute and Initial Management, Complications, Prognosis and Natural History - [103]
David TE, Weiss J, Runeckles K et al.. “Late adverse cardiovascular events after aortic valve-sparing operations in patients with Marfan syndrome.” The Journal of thoracic and cardiovascular surgery (2026). PMID: 42092498 ↗
L4OTHERCited in: Acute and Initial Management - [104]
Lian T, Pai CW, Woznicki E et al.. “Nonsyndromic familial type B aortic dissection exhibits distinct clinical profiles and operative outcomes.” Journal of vascular surgery (2026). PMID: 42082039 ↗
L2OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [105]
Zhao S, Hua X, Zhu D et al.. “SPP1high fibrogenic macrophages mediate protective fibrotic remodeling and promote vascular stability in hypertension-associated aortic dissection.” BMC medicine (2026). PMID: 41840626 ↗
L4OTHERCited in: Acute and Initial Management - [106]
Ouzounian M, Rao V, Manlhiot C et al.. “Valve-Sparing Root Replacement Compared With Composite Valve Graft Procedures in Patients With Aortic Root Dilation.” Journal of the American College of Cardiology (2016). PMID: 27765186 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy - [107]
Itagaki S, Chikwe JP, Chiang YP et al.. “Long-Term Risk for Aortic Complications After Aortic Valve Replacement in Patients With Bicuspid Aortic Valve Versus Marfan Syndrome.” Journal of the American College of Cardiology (2015). PMID: 26046728 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History - [108]
McArthur M, Lee SL, Chiu MZ et al.. “Bracing for Success: Long-term Patient-reported Outcomes of Bracing Therapy for Pectus Carinatum.” The Journal of surgical research (2026). PMID: 42419066 ↗
L4OTHERCited in: Long-term Guideline-Directed Therapy - [109]
MacCarrick G, Afifi RO, Allen R et al.. “Loeys-Dietz syndrome: 2026 updated care management primer.” Genetics in medicine : official journal of the American College of Medical Genetics (2026). PMID: 41988792 ↗
L5REVIEW_NARRATIVECited in: Long-term Guideline-Directed Therapy - [110]
Park I, Cho JH, Sung K et al.. “Impact of Severe Uncorrected Pectus Excavatum on Outcomes After Aortic Surgery in Marfan Syndrome.” The Annals of thoracic surgery (2026). PMID: 41966293 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy - [111]
Xu Y, Xia YH, Bai ZM et al.. “Management strategies for acute type A aortic dissection during pregnancy: a single-center retrospective experience.” BMC pregnancy and childbirth (2026). PMID: 41673593 ↗
L4OTHERCited in: Long-term Guideline-Directed Therapy - [112]
Allen JD, Duong BQ, Brady J et al.. “Pharmacotherapy Risks in Rare Genetic Diseases: Cross-Referencing ACMG Secondary Findings v3.2 List With Clinical Databases.” Clinical and translational science (2026). PMID: 41527333 ↗
L5OTHERCited in: Long-term Guideline-Directed Therapy - [113]
Gaudino M, Girardi LN, Rahouma M et al.. “Editor's Choice - Aortic Re-operation After Replacement of the Proximal Aorta: A Systematic Review and Meta-Analysis.” European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery (2018). PMID: 30037741 ↗
L2SR_OBSCited in: Interventional and Device Therapy - [114]
Burgstaller JM, Held U, Mosbahi S et al.. “A systemic review and meta-analysis: long-term results of the Bentall versus the David procedure in patients with Marfan syndrome.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2018). PMID: 29893811 ↗
L2SR_OBSCited in: Interventional and Device Therapy - [115]
Van Hoof L, Lamberigts M, Noé D et al.. “Matched comparison between external aortic root support and valve-sparing root replacement.” Heart (British Cardiac Society) (2023). PMID: 36650042 ↗
L2RCTCited in: Interventional and Device Therapy - [116]
Al-Thani H, Mekkodathil A, El-Menyar A. “Management and Outcomes of Aortic Dissection in Pregnancy with Marfan Syndrome: A Systematic Review.” Current vascular pharmacology (2020). PMID: 30963974 ↗
L2SR_OBSCited in: Interventional and Device Therapy - [117]
Ricciardi G, Soquet J, Abou-Arab O et al.. “Heart Transplantation After Acute Aortic Dissection in an Adolescent With Marfan Syndrome.” The Annals of thoracic surgery (2021). PMID: 34560040 ↗
L4CASE_REPORTCited in: Interventional and Device Therapy - [118]
Uchida T, Hamasaki A, Kuroda Y et al.. “Aortic Graft Dehiscence After Valve-Sparing Root Replacement.” The Annals of thoracic surgery (2019). PMID: 30794782 ↗
L4CASE_REPORTCited in: Interventional and Device Therapy - [119]
Herrmann FEM, Schramm R, Hagl C et al.. “Aortic Root Replacement and Berlin Heart EXCOR Implantation in Marfan Syndrome.” The Annals of thoracic surgery (2018). PMID: 30266613 ↗
L4CASE_REPORTCited in: Interventional and Device Therapy - [120]
Nabi HA, Dreher L, Bcharah H et al.. “Efficacy and safety of atrial fibrillation ablation in patients with Marfan syndrome: A multicenter analysis.” Heart rhythm O2 (2026). PMID: 42369794 ↗
L2OTHERCited in: Interventional and Device Therapy - [121]
Maron BJ, Chaitman BR, Ackerman MJ et al.. “Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases.” Circulation (2004). PMID: 15184297 ↗
L5GUIDELINECited in: History and Evolution of Treatment - [122]
Forteza A, Evangelista A, Sánchez V et al.. “Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial.” European heart journal (2015). PMID: 26518245 ↗
L1RCTCited in: History and Evolution of Treatment, Complications - [123]
Nicod P, Bloor C, Godfrey M et al.. “Familial aortic dissecting aneurysm.” Journal of the American College of Cardiology (1989). PMID: 2647812 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [124]
Donofrio MT, Engle MA, O'Loughlin JE et al.. “Congenital aortic regurgitation: natural history and management.” Journal of the American College of Cardiology (1992). PMID: 1634673 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [125]
Finkbohner R, Johnston D, Crawford ES et al.. “Marfan syndrome. Long-term survival and complications after aortic aneurysm repair.” Circulation (1995). PMID: 7828300 ↗
L4OTHERCited in: History and Evolution of Treatment - [126]
Pape LA, Tsai TT, Isselbacher EM et al.. “Aortic diameter >or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD).” Circulation (2007). PMID: 17709637 ↗
L4OTHERCited in: History and Evolution of Treatment - [127]
Yun KL, Miller DC, Fann JI et al.. “Composite valve graft versus separate aortic valve and ascending aortic replacement: is there still a role for the separate procedure?” Circulation (1997). PMID: 9386126 ↗
L2OTHERCited in: History and Evolution of Treatment - [128]
Goldfinger JZ, Preiss LR, Devereux RB et al.. “Marfan Syndrome and Quality of Life in the GenTAC Registry.” Journal of the American College of Cardiology (2017). PMID: 28595698 ↗
L2OTHERCited in: History and Evolution of Treatment, Complications - [129]
Silverman DI, Gray J, Roman MJ et al.. “Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival.” Journal of the American College of Cardiology (1995). PMID: 7560600 ↗
L2OTHERCited in: History and Evolution of Treatment - [130]
Januzzi JL, Isselbacher EM, Fattori R et al.. “Characterizing the young patient with aortic dissection: results from the International Registry of Aortic Dissection (IRAD).” Journal of the American College of Cardiology (2004). PMID: 14975480 ↗
L4OTHERCited in: History and Evolution of Treatment - [131]
Ma Y, Zhang X, Jin L et al.. “Social Media Interventions and Postoperative Follow-Up in Congenital Ectopia Lentis: A Randomized Clinical Trial.” JAMA ophthalmology (2025). PMID: 40208617 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History - [132]
Jouini S, Milleron O, Eliahou L et al.. “Online Personal Training in Patients With Marfan Syndrome: A Randomized Controlled Study of Its Impact on Quality of Life and Physical Capacity.” Journal of the American Heart Association (2024). PMID: 39291498 ↗
L1RCTCited in: History and Evolution of Treatment - [133]
Gott VL, Pyeritz RE, Magovern GJ et al.. “Surgical treatment of aneurysms of the ascending aorta in the Marfan syndrome. Results of composite-graft repair in 50 patients.” The New England journal of medicine (1986). PMID: 2938007 ↗
L4OTHERCited in: History and Evolution of Treatment - [134]
Glesby MJ, Pyeritz RE. “Association of mitral valve prolapse and systemic abnormalities of connective tissue. A phenotypic continuum.” JAMA (1989). PMID: 2739055 ↗
L4OTHERCited in: History and Evolution of Treatment - [135]
Hawass Z, Gad YZ, Ismail S et al.. “Ancestry and pathology in King Tutankhamun's family.” JAMA (2010). PMID: 20159872 ↗
L4OTHERCited in: History and Evolution of Treatment, Prognosis and Natural History - [136]
Pfister GC, Puffer JC, Maron BJ. “Preparticipation cardiovascular screening for US collegiate student-athletes.” JAMA (Unknown). PMID: 10735397 ↗
L4OTHERCited in: History and Evolution of Treatment - [137]
Glover DW, Maron BJ. “Profile of preparticipation cardiovascular screening for high school athletes.” JAMA (1998). PMID: 9628714 ↗
L5OTHERCited in: History and Evolution of Treatment - [138]
Cuozzo S, Jabbour J, D'Amico C et al.. “Urgent Relining of a Fenestrated Stent-Graft for Symptomatic Type V TAAA due to Late Type IIIB and IIIC Endoleaks in a Patient With Marfan Syndrome Case Report and Literature Review.” Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists (2025). PMID: 40580078 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [139]
Su C, Zeng L, Lu H et al.. “Case Report: A FBN1 frameshift-and-nonsense mutation and aortic dissection in Marfan syndrome.” Frontiers in cardiovascular medicine (2025). PMID: 40336639 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [140]
Darveau SC, Sylvestre G, Weingarten SJ. “Prenatal Diagnosis of Congenital Paraesophageal Hernia With Gastric Volvulus and Postnatal FBN1 Mutation Confirmation.” Prenatal diagnosis (2025). PMID: 39993998 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [141]
Caro R, Savel P, Moss PI. “Evaluation of Short and Tall Stature in Children.” American family physician (2025). PMID: 40531152 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [142]
Cai X, Chen W, Xue J et al.. “Diagnosis of congenital ectopia lentis: a case report and review of the literature.” Journal of medical case reports (2025). PMID: 40542356 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [143]
McLoughlin D, McGuinness J, Byrne J et al.. “Pravastatin reduces Marfan aortic dilation.” Circulation (2011). PMID: 21911808 ↗
L5OTHERCited in: Complications - [144]
Pilop C, Aregger F, Gorman RC et al.. “Proteomic analysis in aortic media of patients with Marfan syndrome reveals increased activity of calpain 2 in aortic aneurysms.” Circulation (2009). PMID: 19720936 ↗
L3OTHERCited in: Complications - [145]
Yang P, Liu H, Wang S et al.. “PIEZO1 attenuates Marfan syndrome aneurysm development through TGF-β signaling pathway inhibition via TGFBR2.” European heart journal (2025). PMID: 39585648 ↗
L5OTHERCited in: Complications - [146]
Cohen SA, Kalavar M, Sridhar J. “Surgical approach to ocular complications of Marfan syndrome.” Current opinion in ophthalmology (2026). PMID: 41496654 ↗
L5REVIEW_NARRATIVECited in: Complications - [147]
Nariai M, Wada-Hiraike O, Sasabuchi Y et al.. “Aortic dissection during the perinatal period in women with Marfan-related disorders: a retrospective cohort study using the Japanese Diagnosis Procedure Combination database.” The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2026). PMID: 41866242 ↗
L2COHORTCited in: Complications, Special Populations and Prevention - [148]
Arai W, Furuya M, Nakatani Y et al.. “Pulmonary Vascular Abnormalities and Spontaneous Pneumothorax in Loeys-Dietz Syndrome.” Pathology international (2026). PMID: 41492809 ↗
L4CASE_REPORTCited in: Complications - [149]
Elkayam U, Goland S, Pieper PG et al.. “High-Risk Cardiac Disease in Pregnancy: Part II.” Journal of the American College of Cardiology (2016). PMID: 27443948 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History, Special Populations and Prevention - [150]
Franken R, Groenink M, de Waard V et al.. “Genotype impacts survival in Marfan syndrome.” European heart journal (2016). PMID: 26787436 ↗
L2OTHERCited in: Prognosis and Natural History - [151]
Saraber PJMH, Bica LC, Reesink KD et al.. “The clinical relevance of the decelerating effect of angiotensin receptor blockers on aortic growth in Marfan patients; a Bayesian perspective.” International journal of cardiology (2025). PMID: 40288542 ↗
L5SR_OBSCited in: Prognosis and Natural History - [152]
Isselbacher EM, Preventza O, Hamilton Black J et al.. “2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.” The Journal of thoracic and cardiovascular surgery (2023). PMID: 37389507 ↗
L1GUIDELINECited in: Special Populations and Prevention - [153]
Hart DA. “Regulation of Joint Tissues and Joint Function: Is There Potential for Lessons to Be Learned Regarding Regulatory Control from Joint Hypermobility Syndromes?” International journal of molecular sciences (2025). PMID: 39941023 ↗
L5REVIEW_NARRATIVECited in: Special Populations and Prevention - [154]
Warner D, Holmes KW, Afifi R et al.. “Emergency vascular surgical care in populations with unique physiologic characteristics: Pediatric, pregnant, and frail populations.” Seminars in vascular surgery (2023). PMID: 37330246 ↗
L5REVIEW_NARRATIVECited in: Special Populations and Prevention - [155]
Curtis SL, Swan L. “Aortopathy in pregnancy.” Heart (British Cardiac Society) (2022). PMID: 35144984 ↗
L5REVIEW_NARRATIVECited in: Special Populations and Prevention - [156]
Zeng Y, Hu Y, Jiang B et al.. “Unusual combination of acute aortic dissection, Mayer-Rokitansky-Küster-Hauser syndrome, and 46,XX gonadal dysgenesis: A case report.” Frontiers in cardiovascular medicine (2022). PMID: 36440024 ↗
L4CASE_REPORTCited in: Special Populations and Prevention - [157]
Małek Ł, Lemańska A, Śpiewak M. “Pectus Excavatum-A Frequent but Often Neglected Entity in Sports Cardiology.” Diagnostics (Basel, Switzerland) (2025). PMID: 41374337 ↗
L5REVIEW_NARRATIVECited in: Special Populations and Prevention